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INTRODUCTION 
Fine-needle aspiration cytology (FNAC) was performed on a large scale at 
Memorial Hospital, New York, during the 1930s, but during the ensuing years, it 
did not gain much encouragement in United States. The technique had a 
resurgence in Scandinavia during the 1950s and 1960s, where it flourished before 
spreading to other parts of the world. For decades, small samples of tissue have 
been obtained using a needle to diagnose lesions in many anatomical locations. 
Breast lesions were identified as particularly suitable for the technique due to their 
accessibility. The use of smears obtained by aspiration for diagnostic purposes was 
reported as early as 1933, when Stewart’s series of 2,500 specimens included 
almost 500 breast lesions. The publication of cytology results for a series of 2,111 
fine needle aspiration (FNA) samples by Franzen and Zajicek in 1968 established 
the technique as a vital part of the assessment of breast lesions. FNA cytology and 
core biopsy were originally used to diagnose palpable breast lesions. Both 
methods have a high degree of sensitivity and specificity. FNA cytology is an 
excellent method for diagnosing palpable lesions; its sensitivity has been reported 
to be between 89% and 98%5 and its specificity between 98% and 100%. 
Following the introduction of mammographic screening, FNA cytology is 
now also used to diagnose impalpable breast lesions.The sensitivity and specificity 
of stereotactic FNA cytology with impalpable lesions have been reported to be 77–
100% and 91–100% respectively. 
  
 
 
 
 
 
 
AIMS AND OBJECTIVES 
 
1. To study the Epidemology of breast disorders in Tirunelveli medical 
college hospital. 
2. To assess the value of FNAC in the preoperative evaluation of patients 
3. To correlate the findings of FNAC with that of HPE of the excised 
speciment after surgery. 
4. To determine the incidence of malignancy and other Benign lesions of the 
Breast. 
5. The diagnosis of Carcinoma of Breast. 
6. The diagnosis of Fibro Cystic Diseases, Which in most cases can be 
managed medically without the need for surgery. 
7. The avoidance of surgery in Doubtful cases where there is no pressing need 
for operative intervention based on a firm tissue diagnosis. 
8. To recognise early breast cancers where there is scope for breast 
conservation surgery. 
9. To analyse the cost-effectiveness of FNAC. 
 
 
  
 
 
 
 
 
 
CYTOLOGY OF BREAST 
The Breast 
The female breasts are modified sweat glands composed of lobes and 
lobules interspersed with adipose tissue and connective tissue. Ducts drain from 
each lobule. These converge to form a lactiferous duct that drains from each lobe. 
The lactiferous ducts merge just beneath the nipple to form a lactiferous sinus. 
The functional secretory unit in lactation is the terminal duct lobular unit. 
Here, each duct has a lining epithelium surrounded by a thin myoepithelial cell 
layer responsive to oxytocin, the hormone that stimulates lactation. 
Neoplasms may arise in either the ductular epithelium, lobules, or the 
stroma. However, the majority of cancers arise in the ducts. 
 
NORMAL BREAST – HIGH POWER VIEW 
  
 
 
 
 
 
 
Benign lesion 
 
 
At low power, the prominent cysts of fibrocystic changes are shown. The 
cysts are lined by a single epithelial layer of varying height. 
 
 
 
 
These breast ducts demonstrate epithelial hyperplasia. The epithelial cells 
are multilayered. There is no atypia. Thus, just as with fibrocystic changes such as 
fibrosis, cysts, and sclerosing adenosis, there is no increased risk for carcinoma. 
  
 
 
 
 
 
 
 
 
More florid ductal epithelial hyperplasia of the breast is shown here. 
There is a slightly increased risk (1.5 to 2 times normal) for breast carcinoma 
when such changes are present. 
 
 
 
The microscopic appearance of a fibroadenoma. To the right is 
compressed breast connective tissue forming a "capsule" to this mass. The 
neoplasm itself is composed of a fibroblastic stroma in which are located 
elongated compressed ducts lined by benign appearing epithelium.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A small benign intraductal papilloma appears here in a breast duct, 
typically in one of the main lactiferous ducts beneath the areola. Note that the 
epithelial cells show no atypia and that there is a fine pink collagenous stroma 
within the papilloma. An intraductal papilloma may be associated with a serous or 
bloody nipple discharge, or it may cause some nipple retraction. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GYNAECOMASTIA 
Males have a small amount of breast tissue, but it consists of just a few 
ducts, without lobules, in a fibrous stroma. It may be unilateral or bilateral. 
Sometimes it can occur at puberty or sometimes with aging. Gynecomastia may 
occur with cirrhosis of liver, Leydig cell tumors of testis, or with drugs. There can 
be ductal epithelial hyperplasia, or prominent periductular edema as seen here. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The female breast during pregnancy undergoes lobular hypertrophy so 
that following birth lactation can occur. Seen here are lobules filled with pink 
secretions. The breast, which histologically is a modified sweat gland, secretes by 
budding off of portions of cell cytoplasm. 
Incidence of Breast Cancer 
Breast cancer is very rare before age 20 and is rarely diagnosed in women 
younger than age 25. Past that age, the incidence rises steadily to reach a peak 
around the age of menopause. The rate of increase is lessened after menopause, 
but older women are still at increasing risk over time. 
  
 
 
 
 
 
 
Risk Factors for Breast Cancer 
Although a specific cause for breast cancer has not been identified, there 
are risk factors that increase the likelihood that a woman will develop a breast 
cancer. These risks include: 
• Maternal relative with breast cancer. Women whose mother or sister  or 
 aunt had breast cancer, particularly at a younger age, have a   
 greater risk. 
• BRCA1 and BRCA2 genes. The incidence of the BRCA1 gene on 
 chromosome 17 may be 1 in 800 women. The BRCA2 gene on
 chromosome 13 is less frequent but associated with early onset breast
 carcinomas. The presence of these genes may explain some of thefamilial 
 cases, and may be the etiology for about 1% of breast cancers  overall. 
• Longer reproductive span. Women who have an earlier menarche and/or a 
 later menopause, increasing the length of reproductive years, are at 
 greater risk. 
• Obesity. Women who are overweight are at increased risk. In addition,
 increased dietary fat intake is a risk. 
• Nulliparity. Women who have never borne children are at greater risk, 
 while women who have been pregnant are at a lower risk. 
• Later age at first pregnancy. Women who had their first child over age 
 30 are at greater risk. 
  
 
 
 
 
 
 
• Atypical epithelial hyperplasia. Although fibrocystic changes that 
 produce benign breast "lumps" are not premalignant, the presence of 
 atypical changes in ductular epithelium does increase the risk. 
• Previous breast cancer. Women who have had breast cancer in the
 opposite breast are at increased risk for cancer in the remaining breast. 
• Previous endometrial carcinoma. Women who have had adenocarcinoma of 
 the endometrium are at increased risk for breast  cancer. 
Aside from the genetic predisposition, the common factor in many of these 
risks is increased endogenous estrogen exposure over a long time. 
Classification of Breast Cancer 
Breast cancers can be classifed histologically based upon the types and 
patterns of cells that compose them. Carcinomas can be invasive (extending into 
the surrounding stroma) or non-invasive (confined just to the ducts or lobules). 
The tables below identify the major histologic types of invasive and non-invasive 
breast cancers, along with their frequency of all breast cancer types, and overall 
relative 5-year survival (% of patients with that histologic type surviving for 5 
years following diagnosis). The "NOS" categories contain carcinomas not easily 
classified into other histologic types or carcinomas for which minimal tissue was 
available for diagnosis. 
  
 
 
 
 
 
 
Invasive Carcinomas of the Breast 
Histologic Type  
Frequency 
(%) 
5-year 
Survival (%)  
Infiltrating Ductal  Carcinoma  63.6  79  
Infiltrating Lobular  Carcinoma  5.9  84  
Infiltrating Ductal & Lobular 
 Carcinoma  
1.6  85  
Medullary Carcinoma  2.8  82  
Mucinous (colloid)  Carcinoma  2.1  95  
Comedocarcinoma  1.4  87  
Paget's Disease  1.0  79  
Papillary Carcinoma  0.8  96  
Tubular Carcinoma  0.6  96  
Adenocarcinoma, NOS  7.5  65  
Carcinoma, NOS  3.5  62  
  
 
 
 
 
 
 
Non-invasive Carcinomas of the Breast 
Histologic Type 
Frequency 
(%) 
5-year Survival 
(%) 
Intraductal Carcinoma  3.6  >99  
Lobular Carcinoma in situ  
 (LCIS)  
1.6  >99  
Intraductal & LCIS  0.2  >99  
Papillary Carcinoma  0.4  >99  
Comedocarcinoma  0.3  >99  
 
  
 
 
 
 
 
 
 
 
 
 
This is atypical ductal epithelial hyperplasia of the breast. A significantly 
increased risk (5 times normal) for breast carcinoma occurs with cytologically 
atypical epithelial hyperplasia. 
 
 
 
The classic cribriform pattern of intraductal carcinoma of the breast is 
seen here. The neoplastic epithelial cells within the duct show minimal 
hyperchromatism and pleomorphism, but they have holes with sharp margins as 
though punched out by a cookie cutter. 
  
 
 
 
 
 
 
 
 
 
This high power microscopic view demonstrates intraductal carcinoma. 
Neoplastic cells are still within the ductules and have not broken through into the 
stroma. the two large lobules in the center contain microcalcifications. Such 
microcalcifications can appear on mammography. 
 
 
 
Lobular carcinoma in situ (LCIS) is seen here. LCIS consists of a 
neoplastic proliferation of cells in the terminal breast ducts and acini. The cells are 
small and round. Though these lesions are low grade, there is a 30% risk for 
development of invasive carcinoma in the same or the opposite breast. 
  
 
 
 
 
 
 
 
 
 
Comedocarcinoma pattern of intraductal carcinoma, which is 
characterized by the presence of rapidly proliferating, high-grade malignant cells. 
The cells in the center of the ducts with comedocarcinoma are often necrotic and 
calcify, as shown here. This central necrosis leads to the gross characteristic of 
extrusion of cheesy material from the ducts with pressure (comedone-like). 
 
 
Infiltrating ductal carcinoma of breast. Note the infiltration of ill-defined 
glands into the surrounding collagenous stroma. There is also a small 
microcalcification at the lower right of center, a finding that could be seen by 
mammography. About 65 to 80% of breast cancers are of this type. 
  
 
 
 
 
 
 
 
 
 
 
 
Infiltrating ductal carcinoma of breast at low magnification appears to 
radiate from a central area of desmoplasia. This collagenous component gives the 
neoplasm a hard "scirrhous" consistency that is palpable. Such an invasive 
carcinoma may be fixed to underlying chest wall, making it non-mobile. 
 
 
 
 
Invasive lobular carcinoma of the breast.This neoplasm arises in the 
terminal ductules of the breast. About 5 to 10% of breast cancers are of this type. 
There is about a 20% chance that the opposite breast will also be involved, and 
many of them arise multicentrically in the same breast. 
  
 
 
 
 
 
 
 
 
 
 
Invasive lobular carcinoma – high power At high magnification, the 
characteristic "Indian file" strands of infiltrating lobular carcinoma cells are seen 
in the fibrous stroma. Pleomorphism is not great. 
 
 
 
 
Medullary carcinomas account for less than 5% of breast cancers. They can 
sometimes be large, fleshy masses up to 5 cm in size. At low power, sheets and 
nests of cells are surrounded by a lymphoid stroma with little desmoplasia. The 
prognosis with medullary carcinoma is better than for infiltrating ductal or 
lobular carcinoma. 
  
 
 
 
 
 
 
 
 
This variant of breast cancer is known as colloid, or mucinous, 
carcinoma. Note the abundant bluish mucin. The carcinoma cells appear to be 
floating in the mucin. This variant tends to occur in older women and is slower 
growing, and if it is the predominant histologic pattern present, then the prognosis 
is better than for non-mucinous, invasive carcinomas. 
 
 
This variant of breast cancer is tubular carcinoma. The neoplastic cells 
form a single cuboidal layer in small round to teardrop shaped ductules widely 
spaced in a fibrous stroma. The prognosis tends to be better than for an intraductal 
carcinoma. 
  
 
 
 
 
 
 
 
 
Pagets Disease Of Breast: A PAS stain demonstrates mucin within the 
Paget's cells of Paget's disease of the breast. This is evidence for their origin from 
an underlying ductal carcinoma. By immunoperoxidase staining, they will also be 
keratin positive and epithelial membrane antigen positive. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Metaplastic breast carcinoma has elements of squamous metaplasia as 
shown here at high magnification. Such tumors are rare in humans (though 
common in canines). The metaplastic patterns can include cartilagenous, bony, 
and myxoid areas as well. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
INFLAMMATORY CARCINOMA 
The skin overlying the breast has prominent lymphatic spaces filled with 
small metastases from breast carcinoma. Carcinomas often metastasize to 
lymphatics. Breast cancers most often metastasize to the axillary lymph nodes, and 
these nodes are often removed at the time of surgery for breast cancer. 
GRADING  
o  Cytologic grade is the best predictor of disease prognosis in carcinoma in 
 situ but is dependent on the grading system used, such as the Van Nuys 
 classification (high-grade, low-grade comedo, low-grade noncomedo).  
o  The grading of invasive carcinoma is also important as a prognostic 
 indicator, with higher grades indicating a worse prognosis. Microscopic 
 criteria for grading are , 
o  Grading System in Invasive Breast Cancer (Modified Bloom and 
 Richardson)  
  
 
 
 
 
 
 
 
 Score 
 1 2 3 
A. Tubule 
formation 
>75% 10-75% <10% 
B. Mitotic 
count per 
high-power 
field 
(microscope- 
and field-
dependent) 
<7 7-12 >12 
C. Nuclear 
size and 
pleomorphism 
Near normal 
Little variation 
Slightly enlarged 
Moderate variation 
Markedly enlarged
Marked variation 
 
o Cancer is considered grade I if the total score (A + B + C) is 3-5.  
o Cancer is considered grade II if the total score (A + B + C) is 6 or 7.  
o Cancer is considered grade III if the total score (A + B + C) is 8 or 9. 
• Lymphovascular: Lymphatic invasion, vascular invasion, microvessel  
 quantification, and lymphoplasmacytic infiltration are associated with a 
 worse prognosis.  
  
 
 
 
 
 
 
GRADING AND STAGING 
A completely uniform system of grading for breast cancers is not possible 
because of the wide variety of histologic cell types. The cell types themselves, 
along with the invasiveness of the cancer, help to predict the biologic behavior of 
the cancer. A grading system (a modified Scarff-Bloom-Richardson system) 
outlined below utilizes histologic characteristics of the breast carcinoma.  
 
Tubule Formation (% of carcinoma composed of tubular 
structures)  
Score 
>75%  1  
10-75%  2  
less than 10%  3  
Nuclear Pleomorphism  Score 
Small, uniform cells  1  
Moderate increase in size and variation  2  
Marked variation  3  
Mitotic Count (per 10 high power fields)  Score 
Up to 7  1  
8 to 14  2  
15 or more  3  
 
  
 
 
 
 
 
 
The grade is calculated by adding the above scores. The grade correlates 
with survival as follows: 
 
Grade  Score 5-year Survival (%) 7-year Survival (%)  
1  3 to 5  95  90  
2  6 or 7  75  65  
3  8 or 9  50  45  
 
 
 
  
 
 
 
 
 
 
METHODS, MATERIALS AND TECHNIQUES 
THE TRIPLE TEST 
 FNA cytology should always be interpreted in the context of the triple test. 
 The triple test is the recommended approach for the investigation of 
palpable or impalpable breast lesions detected by imaging. It comprises the 
following components: 
•  Clinical breast examination and medical history 
•  Imaging – mammography and/or ultrasound 
•  Non-excision biopsy – FNA cytology and/or core biopsy. 
 The triple test is positive if any of the three components is positive, and 
negative if all the components are negative.The triple test has a sensitivity 
(truepositive rate) of 99.6%, and a specificity of 93%. Irwig and Macaskill (1997) 
have developed models to illustrate the accuracy of the triple test results for 
clinically and mammographically detected breast lesions. 
The aims of the triple test are to: 
•  Maximise the diagnostic accuracy in breast disease 
•  Maximise the preoperative diagnosis of cancer 
•  Minimise the proportion of excision biopsies for diagnostic purposes 
•  Minimise the proportion of benign excision biopsies for diagnostic 
 purposes. 
  
 
 
 
 
 
 
INDICATIONS 
Indications for FNA cytology 
FNA cytology may be indicated in the following clinical situations: 
•  Investigation of palpable masses, regardless of whether they are considered 
 benign or malignant 
•  Investigation of impalpable image-detected masses that are considered 
 likely to be benign or with typically malignant features 
•  Investigation of suspected local recurrence of breast cancer, as suggested by 
 the presence of palpable masses, impalpable image-detected masses, or 
 lymph node involvement 
•  Evaluation of cystic lesions with atypical imaging features 
•  Confirmation of a diagnosis of breast cancer when core biopsy is not 
 available, not possible or contraindicated. 
ADVANTAGES  AND  DISADVANTAGES OF FNACYTOLOGY 
The reliability of FNA cytology depends on the skills of the aspirator, the 
cytopathologist and the histological type of the lesion.The age of the patient, size 
of the lesion and method of detection (clinically detected or image  detected) also 
influence reliability. 
ADVANTAGES 
The relative advantages of FNA cytology, compared with core biopsy, 
include: 
•  The sampling procedure for FNA cytology is quicker to perform than core 
 biopsy 
  
 
 
 
 
 
 
• In most instances FNA cytology does not require local anaesthetic 
•  FNA cytology is generally less traumatic than core biopsy and may be more 
 appropriate for women taking anticoagulant medication 
•  FNA cytology is associated with a low complication rate 
•  FNA cytology results are available relatively quickly (within a few hours in 
 some centres); the presence of a cytopathologist may facilitate an 
 immediate result. 
•  relatively inexpensive to perform. 
DISADVANTAGES 
The relative disadvantages of FNA cytology, compared with core biopsy, 
include: 
•  FNA cytology requires training in the preparation of quality smears 
•  Considerable cytology expertise is required to interpret FNA cytology 
•  FNA cytology is generally inappropriate for the assessment of 
 microcalcifications 
•  FNA cytology does not enable the pathologist to distinguish between DCIS 
 and invasive carcinoma 
•  Definitive diagnosis of some lesions can be difficult to make on the basis of 
 FNA cytology.These include atypical ductal hyperplasia (ADH), lowgrade 
 DCIS, some tubular carcinomas and some invasive lobular carcinomas 
•  FNA cytology may not be the sampling technique of choice for lesions that 
 are relatively hypocellular and yield scanty epithelial material.These 
 include sclerotic fibroadenomas, sclerosing ductal carcinoma, and 
 infiltrating lobular carcinoma. 
  
 
 
 
 
 
 
POTENTIAL COMPLICATIONS  OF  FNA CYTOLOGY 
 Displacement of the epithelium and needle tract implantation are potential 
complications of FNA cytology. 
Displacement of the epithelium 
Displacement of both benign and malignant epithelium into other structures 
may have diagnostic or treatment implications. Displacement may occur into 
stroma, other ducts, skin or vascular and lymphatic spaces. 
Displacement of epithelium may occur with any procedure involving a 
needle, including the insertion of local anaesthetic and guidewires. However, it is 
more common with larger gauge needles, such as those used in core biopsy. Few 
appropriately designed studies have evaluated the risk of an adverse event due to 
displacement of malignant epithelium by FNA cytology or core biopsy. 
Needle tract implantation 
The biological significance of needle tract implantation in the breast is not 
known at this time, though there is evidence from studies of other cancer types 
indicating that the risk of malignancy is increased in those tissues. Rosen 1997) 
reported several cases where fragments of breast carcinoma were found in the 
needle tract following 14-gauge core biopsy. Rosen also reported one case of 
carcinoma cells in the skin of a mastectomy specimen. 
PERFORMING FNA CYTOLOGY  
Recommended steps involved in adequately preparing a woman for FNAC. 
Before the procedure 
•  Explain why the procedure is needed, and the expected outcome 
•  Ask how much detail the woman would like to know about the procedure 
  
 
 
 
 
 
 
 before explaining it. The information may include: 
° Where the procedure might take place, and who will perform it 
° Any tests needed before the procedure 
° What the woman will need to do before the procedure 
° What the woman is likely to experience during and after the procedure 
•  Encourage the woman to talk about her concerns, such as pain, fear, death, 
 embarrassment 
•  Ask the woman what she thinks she can do to cope 
•  Enquire about, and reinforce, previous coping strategies (eg relaxation
 techniques and imagery). 
During the procedure 
•  Provide information about what will be done and how it will feel 
•  Give the woman control, where possible (eg ask her to tell you when she is 
 ready to begin) 
•  Encourage the use of coping strategies. 
After the procedure 
•  Encourage the use of coping skills (eg relaxation techniques and imagery) 
•  Encourage the woman to state her needs and reframe her complaints into 
 requests 
•  Arrange follow-up and support 
  
 
 
 
 
 
 
Choosing the guidance technique 
Available guidance methods are: 
•  Clinical guidance for palpable lesions 
•  Ultrasound and stereotactic mammographic guidance for impalpable and 
 palpable lesions that can be visualised by the imaging technique. 
Comparison of guidance techniques 
Guidance techniques: 
 Guidance techniques 
Parameters Clinical Ultrasound Stereotactic 
Speed +++ +++ + if not digital 
++ if digital 
Ease and 
comfort of 
the woman 
+++ 
 
+++ 
 
+ if upright 
++ if prone 
 
Ease and 
comfort of 
the clinician 
performing 
the 
procedure 
+++ 
 
+++ 
 
+ if upright 
++ if prone 
Flexibility of 
approach 
 
+++ +++ ++ 
Complication 
rate 
+ 
 
+ 
 
+ 
 
Code: +++ high, ++ moderate, + low 
  
 
 
 
 
 
 
EQUIPMENT REQUIRED FOR   FNACYTOLOGY 
Contents of tray or trolley for FNA cytology sampling 
The following items are typically required for FNA cytology sampling: 
• Sampling needle: 
• Venipuncture needle or specifically designed biopsy needle depends on the 
 guidance technique and preference of the operator. 
• Typically 22–25-gauge. 
• Length – depends on the guidance technique and preference of the operator. 
• Syringe (10–20 ml). 
• Syringe holder +/- extension tubing. 
• Alcohol or iodine preparation cleansing agent. 
• Swabs. 
• Gloves. 
• Adhesive dressing. 
• Pencil for labelling slides, pen for labelling specimen containers. 
• Local anaesthesia, needles and syringe if required. 
• Glass slides and transport medium, if required. 
• Protective cover for ultrasound probe, if ultrasound-guided procedure. 
• Gel or other coupling fluid, if ultrasound-guided procedure. 
• Needle guides, if mammography-guided procedure. 
• Koplin – Jar for transport. 
• Laboratory request form. 
  
 
 
 
 
 
 
TECHNIQUES OF ASPIRATION 
 This can be described by the following 4 steps, which are done in 
sequence without any time gap. 
1. Introduction of the needle 
Attach the needle with syringe. The syringe with the needle is manipulated 
with dominant hand while the biopsy site is stabilised with the other hand. The 
needle is introduced centrally into small masses and peripherally into large ones, 
particularly those with necrotic core. 
2. Creating and maintaining the negative pressure 
 Once the needle is within the mass a negative pressure is created by 
retraction of the plunger to the 10 cc mark.Adequade negative pressure (-300cm 
H2O) is created and maintain with the syringe plunger pulled back to 10ml. This 
negative pressure should be maintained till the required amount of material is seen 
in the hub of the needle. The functions of the negative pressure is not to tear cells 
from the tissue but merely to hold the tissues against the sharp-cutting edge of the 
needle. The softer tissue components protrude over the edge are cut or scrapped 
off and accumulate in the lumen ias the needle advances through the tissues. 
The maintenance of the negative pressure is easier if a syringe holder is 
used. In other cases the negative pressure can be maintained by the Bracer thumb 
technique using the dominant hand while the other hand steadies the biopsy site. In 
this technique the medial three fingers grip the retracted plunger against the palm 
while the thumb and the index finger are positioned against the back of the barrel, 
preventing it from retracting and steadying it’s biopsy site. Some experienced 
operators, free their left hand after placing the needle exactly where it is desired 
and use both hands to maintain the negative pressure. In this study the braced 
thumb technique was used to maintain the negative pressure. 
  
 
 
 
 
 
 
3. Needle manoeuver under negative pressure 
To obtain an adequate specimen, the needle must be manoeuvered within 
the circumscribed area. An up and down motion, a fan path with short stabs or a 
corkscrew motion. Nothing is usually visible in the body of the syringe between 
the bottom of the pluger and the needle head except in cystic aspiration or 
haemorrhagoc aspirations. Sometimes the aspirate may be seen at the hub of the 
needle. If a cyst is encountered it is emptied completely and the third is collected 
for indirect smearing. If the blood is observed within the syringe needle 
manoeuvers should be halted, the needle withdrawn and another specimen 
procured. 
4. Release of negative pressure and withdrawal 
The negative pressure is released prior to the needle along with the syringe 
is withdrawn. Centrifugal force prevents expulsion of the specimen and possible 
tumour seeding between the mass and skin surface. Failure to comply with this 
step may result in air rushing up the needle and loss of specimen into the body of 
the syringe. The syringe and the attached to it, is gently withdrawn from the skin. 
Air Reservoir Technique of Aspiration 
Here about 5 cc of air is aspirated into the syringe prior to the introduction 
of the needle. After the introduction of the needle into the required site, the syringe 
is pulled to full suction and the manoeuvers of the needle are carried out as 
described previously. After completion of aspiration, the plunger is released. This 
fall is suction allows plunger to return to the original 5cc mark. According to the 
proponents of this technique, this ensures a more uniform distribution of aspirated 
material on the glass slide and eliminated the necessity for the removal of syringe 
from  the needle. 
  
 
 
 
 
 
 
Non-Aspiration Technique of Needle Sampling 
It is a useful innovation by Santos. JE and Leiman G. (1988). 
It involves grasping the needle itself, without an attached syringe and 
moving it rapidly within the lesion. If the lesion is not cystic and if the aspirate are 
haemorrhagic the non-aspiration technique may give better, cleaner and less 
haemorrhagic material. It also allows detection of more subtle differences in the 
texture of tissue and may allow smaller lesions to be sampled. 
Completion of Aspiration 
After the needle is withdrawn, the puncture site should be examined for any 
possible bleeding or haematoma and the patient is reassured that the procedure is 
over and she will not have any discomfort. The patient is asked to sit up after the 
completion of the procedure and exert firm pressure over the site for about 5 
minutes. 
Aspiration vs capillary technique for FNA cytology 
Most operators use a suction or aspiration technique for FNA cytology, 
using a syringe alone or with a syringe holder. Extension tubing may also be used. 
The use of suction has been shown to reduce the rate of inadequate/non-diagnostic 
sampling from benign lesions. The aspirator may choose to convert from a non- 
aspiration technique if the lesion yields limited cellular material or if the lesion 
feels fibrous. Some operators prefer a non-suction or capillary technique, which 
has the advantages of enhancing fingertip sensitivity and needle control and 
reducing the risk of blood contamination. Conversion to an aspiration technique is 
recommended if the lesion is fibrous or yields limited cellular material. 
  
 
 
 
 
 
 
Complications of FNA cytology and strategies to minimise or avoid them. 
Complication Comment Strategies to minimise 
or avoid complications 
Pain Discomfort is common 
but pain is typically 
minimal 
Can be minimised by: fully explaining 
the procedure; using local anaesthesia 
as required with FNA cytology, and 
routinely with corebiopsy; and (in 
some cases) using analgesic and 
anxiolytic medication 
Bruising Minimal bruising is 
common 
Bruising may be difficult to avoid 
entirely, especially in older women. 
Haematoma Uncommon; likelihood 
increased by the use of 
anticoagulants, 
including 
aspirin 
Both can be minimised by 
compressing the biopsy site both in 
between sampling and at the 
completion of the procedure.When 
large core biopsies are performed or 
the lesion is thought to be vascular, 
then it is recommended local 
anaesthesia be used with a 
vasoconstrictor 
Infection Rare Can be avoided by careful skin 
cleansing and by use of sterile 
disposable items and equipment 
Fainting Uncommon 
May present special 
difficulty 
when using upright 
stereotactic systems 
Can be minimised by treating anxiety, 
fully explaining the procedure, 
providing analgesia or anaesthesia 
where appropriate, and performing 
the procedure with the patient 
lying down 
Pneumothorax A rare complication, 
but the most serious 
one. The risk is 
increased in very thin 
women or if the lesion 
is close to the chest 
wall, in the upper inner 
quadrant or high 
in the axilla 
Can be avoided by taking care 
not to angle the sampling needle 
towards the chest wall, but rather 
parallel to it. Pneumothorax can be 
minimised by monitoring the 
needle position with imaging 
  
 
 
 
 
 
 
PREPRATION AND PROCESSING OF FNA CYTOLOGY  SPECIMENS 
The principal aims for FNA cytology slide preparation is to make a thin 
smear that is not subject to crush artefact, and to allow rapid air-drying of air-dried 
slides and rapid fixation of wet-fixed slides. One commonly used method of 
preparing slides is as follows: 
 Expel a drop of the aspirated fluid onto two of the pre-labelled glass slides. 
If all the material is expelled onto one slide, it can be split simply by touching the 
second slide to the surface and separating them again. The material can be spread 
in several ways.The quickest (and probably easiest) method is illustrated in  
Figure 1. 
A method for preparing slides for FNA cytology 
 
 
 
 
 
 
 
Note: No excessive downward pressure or surface squash should be used as this 
will distort the cells and may render the slides uninterpretable. 
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The following items should be available and prepared before the procedure: 
• Frosted ended slides labelled with the patient’s name and date of birth. Theuse of 
two identifiers is recommended, especially if more than one woman  is to have an 
aspirate at the same clinic 
• Fixative solutions 
• A rapid Romanovsky stain, if the material is to be assessed for adequacy at the 
time of the aspirate. Any wet-fixed slides can be stained later in the  laboratory. 
• A balanced salt solution in which the needle can be rinsed 
• Slide trays or plastic slide carriers for transport. 
Fixation of slides for FNA cytology 
Slides may be fixed as follows: 
1. Wet-fixed slides: Immediate placement into a Coplin jar containing either 
95% ethanol or Carnoy’s solution. (If Carnoy’s or modified Carnoy’s solution is 
used, then the slides should be transferred to 95% ethanol after five minutes, to 
avoid excessive cell shrinkage). 
2. Air-dried slides: Rapid air-drying either by gently waving the slide in the 
air or by using a hair drier on a cold or low heat setting. Blowing from the mouth 
should not be used to air-dry slides. It is important to ensure the slide is dry before 
it is fixed.The slide can then either be placed in methanol for at least 30 seconds, 
or transported to the laboratory where it can be fixed at a later stage. 
 
  
 
 
 
 
 
 
Staining of slides for FNA cytology 
A rapid Romanovsky stain, can be used if the material is to be assessed for 
adequacy at the time of the aspirate.Any wet-fixed slides can be stained later in the 
laboratory.  
One method of staining slides is as follows: 
1. Air-dried slides can be stained at the time of the procedure using a rapid 
 Romanovsky-type stain.  
2. After rinsing in water, the slide can be viewed under the microscope and 
 assessed for adequacy. 
3. Wet-fixed slides are stained with a Papanicolaou stain. 
FIXATION AND STAINING USED IN MY STUDY 
We used wet fixation method using isopropyl alcohol followed by staining 
with hematoxylin and eosin as follows. 
12-24 hours after fixation the slides are taken through descending grades of 
alcohol (i.e. 80%, 75%, 50%) to water. 
Then slides were covered with Harn’s Hematoxylin stain for about 3 
minutes. 
The slides were rinsed in tap water for about 1 – 2 minutes. 
Slides were then treated with acid – alcohol for a few secons till the excess 
stains are cleared and only nuclei retain the stain. 
The slides were covered with 1% eosin solution for about 1 minute and was  
Rinsed in water and allowed to dry. 
Then the  slides were ready for scrutinization under microscope. 
  
 
 
 
 
 
 
Processing needle-rinse material from FNA 
After the slides have been made, material remaining in the needle and 
syringe may be utilised for further studies such as ER and PR assays. Needle 
contents may be extracted by rinsing with a balanced salt solution, and used in 
cytospin or cell block preparations. If a cell block is required, a separate pass can 
be placed into the solution. 
Processing cyst fluids obtained via FNA 
 Although it is not standard practice to submit cyst fluid from cysts for 
cytological evaluation, cyst fluid should be sent for cytological evaluation if any 
of the following apply: 
• It is bloody or serosanguinous 
• There is a residual palpable mass or solid lesion on ultrasound45 
• Imaging studies indicate that the cyst is complex 
CODING FOR FNAC REPORT 
Diagnostic category   Corresponding numerical code 
• Inadequate/insufficent       1 
• Benign         2 
• Atypical/indeterminate       3 
• Suspicious of malignancy      4 
• Malignant         5 
  
 
 
 
 
 
 
COMMON PITFALLS IN THE INTERPRETATION OF FNACYTOLOGY 
FALSEPOSITIVE   DIAGNOSES  IN  FNACYTOLOGY 
False positive diagnoses in FNA cytology occur at a rate of less than 1%, 
and are frequently due to difficulties with interpretation. Conditions associated 
with false positive diagnoses include: 
• Fibroadenoma with atypical features. This is the lesion most commonly 
mistaken for cancer, especially when there is sub-optimal cell preservation,  as the 
epithelial cells may be large and dissociated. 
 However the presence of bare bipolar nuclei should prevent a diagnosis of 
malignancy. 
• Mass or thickening associated with lactation. A clinical history is most 
important to prevent a false positive cytological diagnosis. During pregnancy, 
lactation, or post lactation, most of the cells are acinar and dispersed with 
prominent nucleoli. However, the presence of abundant cytoplasm, vacuolation 
and a lipo-proteinaceous background should prevent misdiagnosis, especially 
when used in conjunction with the triple test. 
• Radial scar with hyperplasia. Ductal hyperplasia is usually an incidental 
histological finding, but when associated with radiological findings suggestive of 
malignancy (eg a radial scar), differentiation from a well differentiated carcinoma 
can be difficult. Bare bipolar nuclei are usually a feature. It is important that a 
definite diagnosis of malignancy is not made if bare bipolar nuclei are present with 
the atypical cells. 
• Papilloma. It is not possible to reliably distinguish between papilloma, atypical 
papilloma, intracystic papillary carcinoma and invasive papillary carcinoma on 
  
 
 
 
 
 
 
cytological material alone. Core biopsy may provide a definitive diagnosis in some 
papillary lesions.The clinical and imaging findings may also overlap. Excision 
biopsy is recommended following a diagnosis of a papillary lesion on FNA 
cytology. 
• Radiation changes. The more widespread use of breast conserving surgery has 
resulted in an increased use of breast irradiation. Radiationinduced epithelial 
atypia is common in benign breast tissue after treatment.A diagnosis of 
malignancy should be made only if all cytological criteria are met. Similar 
problems may arise following chemotherapy. 
• Fat necrosis. Mesenchymal cells or histocytes may resemble abnormal epithelial 
cells but the presence of inflammatory cells, foamy macrophages and 
multinucleated histiocytic giant cells should avoid a false positive diagnosis.This 
is one lesion for which the result of the triple test may be misleading, as fat 
necrosis is a lesion that can mimic carcinoma both clinically and on imaging. 
• Atypical apocrine cells. Apocrine carcinoma is rare, whereas apocrine cells in 
fibrocystic change are common.The differential diagnosis between apocrine 
metaplasia and apocrine carcinoma can occasionally be difficult. 
• Gynecomastia. The cellularity of the smears is highly variable, and epithelial 
atypia is common. Bare bipolar nuclei are present and a diagnosis of malignancy 
should not be made unless all the cytological criteria are met. 
• Phyllodes tumour. This is a stromal neoplasm with a biphasic pattern. In some 
cases, the associated epithelial hyperplasia may result in a false positive 
diagnosis.Again, the presence of bare bipolar nuclei and assessment of the stromal 
fragments should prevent a malignant diagnosis. 
  
 
 
 
 
 
 
• Adenomyoepithelioma. This is a rare tumour, for which large atypical 
epithelioid cells and spindled cells are common features. Bare bipolar nuclei are 
usually numerous and should prevent a definitive diagnosis of malignancy. 
• Tubular adenoma. This is much less common than fibroadenoma but is cellular 
and shows marked dispersal, microacini and prominent nucleoli. 
 Bare bipolar nuceli are present. 
• Granular cell tumour. This is a rare soft tissue tumour which can occur in the 
breast. Dispersed cells with granular cytoplasm, combined with suspicious 
radiological features, make this lesion a pitfall. However, the granular cells do not 
show malignant criteria. Maintaining strict cytological criteria for malignancy will 
assist in keeping false positive diagnoses to a minimum. 
FALSE NEGATIVE  DIAGNOSES  IN  FNACYTOLOGY 
False negative diagnoses in FNA cytology are more common than false 
positive diagnoses, and have been reported to be between 3% and 24%.Sampling 
error is the most common reason for a false negative diagnosis. FNA cytology is 
highly dependent on the skill and experience of the aspirator. A false negative 
result can also be due to interpretation error. Situations and conditions associated 
with false diagnoses in FNA cytology include: 
• Some lesions may be more difficult to sample. Examples of situations that may 
result in sampling difficulty include: 
 ° Small malignant lesions are a special problem, particularly those that are 
 well differentiated and sclerotic, as the cell yield is low and cells may be 
 difficult to distinguish from benign cells.This may result in a false negative 
 diagnosis 
  
 
 
 
 
 
 
° For mass lesions that are difficult to feel, such as those deep in the breast, 
 ultrasound guided FNA cytology may be useful 
° If the lesion is close to the chest wall, it may be difficult to obtain 
 sufficient cells. Ultrasound guidance may increase the yield. 
• Well-differentiated grade 1 carcinomas may be difficult to diagnose, as the cell 
yield may be poor or there may be only mild cellular atypia 
• Infarcted papilloma. Infarction causes cell dispersal. Recognition of degenerate 
columnar forms should prevent a diagnosis of malignancies  
• Invasive lobular carcinomas may yield few cells, which are often difficult to 
distinguish from benign cells. They are often mixed with benign ductal elements 
• Low-grade DCIS, some tubular carcinoma and cribriform carcinoma may yield 
deceptively ‘benign’ aspirates  
• Inflammatory carcinomas by definition show involvement of the dermal 
lymphatics by carcinoma.An adequate sample can be difficult to obtain and 
ultrasound guidance is advised if no definite mass is palpable 
• Necrosis may be present in the centre of a high-grade carcinoma. It is important 
to sample the edge of such a lesion, either by increasing the amplitude of the 
needle passes to achieve passage of the needle through the lesion, and/or by 
specifically aiming for the edge of the lesion as palpated or with image 
guidance.The use of a needle without aspiration may also be useful 
• Sclerosis is a potential cause of a low cell yield  
• Papillary carcinomas may yield numerous cells, but differential diagnosis ofmost 
papillary lesions requires excision and examination of the whole lesion and 
capsule 
  
 
 
 
 
 
 
 
• Mucinous tumours are often well differentiated and the cell yield may be poor. 
The presence of mucin raises the possibility of a mucinous tumour. 
 Application of the triple test should reduce the incidence of missed cancers 
when there is a false negative cytology result. 
TECHNIQUES FOR REDUCING FALSE POSITIVE AND FALSE 
NEGATIVE  RESULTS   IN  FNA CYTOLOGY: 
To reduce false positive and false negative results in FNA cytology, it is 
recommended that: 
• A multidisciplinary approach with appreciation of the importance of theclinical 
and imaging findings (triple test) is adopted 
• Imaging is used to sample lesions difficult to localise or palpate 
• There is adequate training of operators 
• A minimum of three passes is considered standard practice.The presenceof a 
pathologist or cytoscientist at the procedure is helpful to assess adequacy of the 
specimen, otherwise multiple passes are required. If the specimen is still 
inadequate, core biopsy should be performed 
• Slides are well spread,well prepared and well fixed 
• There is adequate training of cytopathologists in cytology as well as histology 
• Services and individuals participate in quality assurance programs. 
  
 
 
 
 
 
 
 
Needle type Sensitivity Specificity  
Fine-needle 
aspiration 
(FNA) 
52-95% 95-100% 
Tru-Cut 68-84% 100% 
Biopty cut 
18G 93-96% 100% 
Biopty cut 
14G 88-98% 100% 
Mammotome 96-99% 100% 
 
Minimum standards for FNA cytology 
 
Performance indicator FNA cytology     Minimum Standard 
Absolute sensitivity        > 60%  
Complete sensitivity       > 80%  
Positive predictive value       > 98%  
(PPV)/malignant 
 
False positive rate        < 1%  
False negative rate        < 6%  
Inadequate sample rate       < 25% 
False negative or inadequate rate      N/A  
 
  
 
 
 
 
 
 
PATHOLOGY REQUEST FORM FOR FNA CYTOLOGY 
PATHOLOGY REQUEST 
Date: ____ / ____/ ____ 
Patient Name:___________________________ 
Date of Birth: ___/___/___ 
Address: ________________________________ 
________________________________________ 
_________________________________________ 
Requesting clinician – Name : _________________ 
      urgent request   routine request 
If urgent, relay report by: mobile phone no _____________  
Request     cytology   histology  receptors   other___________ 
Specimen 
Date: ____ / ____/ ____ Time: ___________ 
• Site sampled:  breast   lymphnode   skin  other _______ 
• Site position: side + ‘o’clock’ ___________ distance from nipple _________ 
Guidance:   palpation  stereotaxis   ultrasound 
 
Site of lesion (specify on diagram)    Specimen radiology: 
           done 
        accompanies specimen 
        microcalcification present 
                             
 
 
 
 
History: 
Medical history: ____________________________________________________ 
_________________________________________________________________ 
Clinical findings: ___________________________________________________ 
Left Right 
  
 
 
 
 
 
 
Imaging findings: 
stellate lesion simple cyst 
circumscribed opacity complex cyst 
asymmetric density well defined hypoechoic 
microcalcifications ill defined hypoechoic 
microcalcifications & mass microcalcifications & mass 
disturbance of architecture disturbance of architecture 
other (specify) ____________ other (specify)_____________ 
Provisional diagnosis:_______________________________________________ 
__________________________________________________________________ 
_________________________________________________________________ 
Copies of report to: ________________________________________________ 
Managing clinician: ________________________________________________ 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
OBSERVATION AND RESULTS 
 “The only function of FNAC is to differentiate neoplastic from non 
neoplastic tissue” this statement by FERGUSSEN in 1937 may still be valid. 
  289 patients was enrolled for this study , conducted between July 2003 to 
February 2006. The age group of patients selected for this study ranged from 15 
years to 88 years.  
EPIDEMOLOGY OF BREAST DISORDERS IN TIRUNELVELI 
MEDICAL COLLEGE HOSPITAL: 
 The total number of Female Inpatients during the period of this study was 
53,723.The Percentage of Female Inpatients with Breast disorders (261) in 
TVMCH during this study period was 0.48 %. 
 The Percentage of female inpatients having Breast cancer (134) during this 
study period was 0.249 %. 
 Total number of major cases performed in surgery dept during this study 
period was 19,312.The Percentage of Breast surgeries (289) in TVMCH during 
this study period was  1.49 %.  
 Out of the 289 patients 28 patients were male. TABLE I and TABLE 11 
shows distribution of patients according to their sex and age. 
The 289 patients selected were clinically examined, investigated, diagnosed 
and was subsequently operated upon. TABLE 1V shows the distribution of 
patients according to their preoperative FNAC diagnosis. 
  
 
 
 
 
 
 
FNAC was done for all the 289 patients. All the patients enrolled in this 
study were in-patients and all the patients were followed up ,during surgery and 
after discharge, and their HPE reports were collected by me personally. 
All the 289 patients readily agreed for the procedure, after proper 
explanation. Patients showing acellular smear or paucicellular smear were 
subjected to repeat FNAC. 
TABLE III. shows the result of FNAC and the distribution of patients under 
each category. Out of the 289 patients the number of patients diagnosed under 
various diseases as per FNAC report is given in TABLE 1V. 
All the 289 patients underwent surgical procedure based on their clinical 
and FNAC diagnosis. TABLE VI shows the distribution of patients according to 
the surgery done. 
Histopathological study was done for all the excised specimens of the 289 
patients and the reports were obtained from the pathology department. TABLE V 
shows the distribution of histopathological report. 
The results of the HPE were then compared with FNAC report of the 
patient and the correlation was noted. TABLE 1X shows the comparison between 
HPE and FNAC. 
 
  
 
 
 
 
 
 
TABLES AND CHARTS 
 
I. SEX DISTRIBUTION OF SAMPLE GROUP 
 
 
Sl.No. Sex Number % Distribution 
1 Male 28 09.68 % 
2 Female 261 90.31 % 
Total 289 100 % 
 
 
 
II. AGE WISE DISTRIBUTION OF SAMPLE GROUP 
 
 
Sl.No Age Group No. % Distribution 
1 0-10 0 0 
2 10-20 42 14.53 % 
3 20-30 63 21.79 % 
4 30-40 61 21.10 % 
5 40-50 58 20.06 % 
6 50-60 43 14.87 % 
7 60-70 19 06.57 % 
8 70-80 2 0.69 % 
9 80-90 1 0.34 % 
Total 289  
 
  
 
 
 
 
 
 
III. FNAC REPORT  : DISTRIBUTION OF PATIENTS ACCORDING TO 
CATEGORY 
 
Report Category Number 
Imaging Abnormality detected/Negative 
Aspiration (Category1) 3 
Benign Findings (Category2) 149 
Indeterminate (Category3) 0 
Suspicious of malignancy (Category4) 7 
Malignant (Category5) 130 
Total 289 
 
IV. FNAC REPORT  : DISTRIBUTION OF PATIENTS ACCORDING TO 
DIAGNOSIS 
Diagnosis Number 
 Ductal Carcinoma 129 
Fibroadenoma 106 
Fibrocystic Disease 9 
Phyllodes Tumor 10 
Gynaecomastia 24 
Medullary Carcinoma 1 
Acellular Smear 3 
Suspicious Of Malignancy 7 
Total 289 
 
  
 
 
 
 
 
 
V. HPE REPORT - DISTRIBUTION OF PATIENTS 
 
Diagnosis Number 
Infiltrating Ductal Carcinoma 134 
Fibroadenoma 106 
Fibrocystic Disease 9 
Phyllodes Tumor (Benign) 11 
Phyllodes Tumor (Malignant) 1 
Gynaecomastia  26 
Medullary Carcinoma 2 
Total 289 
 
 
 
VI. DISTRIBUTION OF PATIENTS ACCORDING TO SURGERY 
 
Sl.No Surgery No. Of Patient 
1. Modified Radical Mastectomy (MRM) 137
2. Simple Mastectomy (SM) 11
3. Excision 115
4. Webster’s Procedure 26
Total 289 
  
 
 
 
 
 
 
VII. FALSE NEGATIVE CASE 
 
 
 
 
VIII. DISTRIBUTION ACCORDING TO MENSTRUAL AGE 
 
 
 
Sl.No Surgery No. Of Patient 
1. Prepubertal 3 
2. Menstrual 172 
3. Post Menopausal 86 
Total 261 
 
 
Sl.No. FNAC 
Report 
No Of 
Cases 
HPE Diagnosis Probable Reason For 
Negative Report 
1. Acellular 
smear 1 Fibro Adenoma Sampling Error 
2. Acellular 
smear 2 Gynaecomastia Sampling Error 
3. Fibro 
adenoma 1 Phyllodes Interpretation Error 
  
 
 
 
 
 
 
IX. FNAC : HPE COMPARISION 
 
 
 
Sl. No. Diagnosis 
HPE 
Report By FNAC Accuracy 
1. Infiltrating Ductal Carcinoma 134 129 96.26 % 
2. Fibroadenoma 106 105 99.01 % 
3. Fibrocystic Disease 9 9 100% 
4. Benign  Phyllodes Tumor 11 10 90.90 % 
5. Malignant Phyllodes Tumor 1 0 0% 
6. Gynaecomastia 26 24 92.3% 
7. Medullary Carcinoma 2 1 50% 
 
  
 
 
 
 
 
 
I.SEX DISTRIBUTION OF SAMPLE GROUP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II. AGE WISE DISTRIBUTION OF SAMPLE GROUP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sex Distribution of Sample Group
9.68%
90.31%
Male Female
0
42
63 61 58
43
19
2 1
0
10
20
30
40
50
60
70
No.
0-1
0
10
-20
20
-30
30
-40
40
-50
50
-60
60
-70
70
-80
80
-90
AGE GROUP
AGE WISE DISTRIBUTION OF SAMPLE GROUP
  
 
 
 
 
 
 
III. FNAC REPORT  : DISTRIBUTION OF PATIENTS ACCORDING TO 
CATEGORY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV. FNAC REPORT  : DISTRIBUTION OF PATIENTS ACCORDING TO 
DIAGNOSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISTRIBUTION OF PATIENTS ACCORDING TO DIAGNOSIS
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V. HPE REPORT - DISTRIBUTION OF PATIENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VI. DISTRIBUTION OF PATIENTS ACCORDING TO SURGERY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MRM –  MODIFIED RADICAL MASTECTOMY 
SM    –   SIMPLE MASTECTOMY 
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VII. FALSE NEGATIVE CASE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VIII. DISTRIBUTION ACCORDING TO MENSTRUAL AGE 
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IX. FNAC : HPE COMPARISION 
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IDC - INFILTRATING DUCTAL CARCINOMA. 
 
FA - FIBRO ADENOMA. 
 
FCD - FIBRO CYSTIC DISEASE. 
 
GM - GYNAECOMASTIA. 
 
BP - BENIGN PHYLLODES TUMOR. 
 
MP - MALIGNANT PHYLLODES. 
 
MC - MEDULLARY CARCINOMA. 
 
SM - SUSPICIOUS OF MALIGNANCY 
 
AS - A CELLULAR SMEAR 
  
 
 
 
 
 
 
DISCUSSION 
From Table I it may be seen that female patients far outnumber male 
patients, confirming the fact that breast diseases are more common in females out 
of 289 patients FNAC was inconclusive in only 4 patients, indicating the 
usefulness of the procedure. 
After the arrival of HPE report, the FNAC report of each patient was 
compared with the corresponding HPE report. 
ACCURACY OF FNAC 
TABLE IX, shows the number of FNAC reports, subsequently confirmed 
by HPE.from the table it may be observer that the diagnostic accuracy was 96.26 
% in diagnosing infiltrating ductal carcinoma, 99.01 % in diagnosing 
fibroadenoma,100 % in diagnosing fibrocystic disease, 90.9 % in diagnosing 
phyllodes tumor, 92.3 % in diagnosing gynaecomastia, and 50 % in diagnosing 
medullary carcinoma in this study. 
FNAC gave a category IV report in a case of malignant phyllodes tumor. The 
accuracy was low in diagnosing malignant phyllodes tumor, benign phyllodes 
tumor, and medullary carcinoma. 
FALSE NEGATIVE RESULTS: 
 Totally there were 4 false negative cases encountered in this study, 
including 3 acellular smears. 
These three cases were examples of sampling errors. 
 Another case of phyllodes tumor was reported as fibroadenoma. It was an 
example of interpretation error. 
  
 
 
 
 
 
 
 In this study the overall false negative rate was 1.38 %.sampling error was 
responsible for most of the negatives, which can be brought down using guidance 
techniques. 
SENSITIVITY: 
 The sensitivity of this study was 96.26 % for Breast malignancy and 95.32 
% for benign Breast disorders.There was no False positive cases in this study. 
POSITIVE PREDICTIVE VALUE OF POSITIVE TEST:  
(FOR MALIGNANCY)  
 PPV in this study was 96.26 % ,for diagnosing breast malignancy. This 
reflects the usefulness of FNAC in predicting malignant conditions of the breast, 
based on which definite treatment strategy can be planned. 
Cost effectiveness of FNAC 
 FNAC is sensitive and direct method for identifying malignant Breast 
Tumors. the diagnostic sensitive reported in the literature varies, it is usually 
above 95%. The low cost of FNAC is appealing especially considering the 
increasing financial restrictions being placed on laboratory test. 
NEWER DEVELOPMENTS 
 1. Non aspiration method is quite useful if the aspirate is haemorrhagic. 
2. Development in radiology helped to do guided aspiration from deep seated 
 tumors and axillary lymphodes. 
3. Recently fine needle aspiration samples are used in other sophisticated 
 procedures like a) morphometric techniques viz, planimetric methods, 
 flowcytometry and single cell microspectrometry b) Study under electron 
 microscopy c) immunocytohistochemistry procedures. 
  
 
 
 
 
 
 
RECENT STUDY REVIEWS 
1) Fine-needle aspiration cytology vs. core biopsy in the diagnosis of breast lesions. 
Diagn Cytopathol. 2003 Dec;29(6):344-8. 
 
BERNERA, DAVIDSON B.Department of Pathology, Division of Cytology, The 
Norwegian Radium Hospital, University of Oslo, Montebello N-0310 
Oslo,Norway.aasmund@labmed.uio.no. 
 
Fine-needle aspiration cytology (FNAC) is an established, highly accurate method for 
diagnosing breast lesions The aim of this study was to evaluate the accuracy of FNAC 
and compare the quality assessment parameters of FNAC in palpable and nonpalpable 
breast lesions. A total of 4,367 FNAC samples from the years 1999-2001 was reviewed. 
Of these, corresponding histology results were available for 1,275 lesions, of which 1,248 
were primary breast epithelial lesions.High specificity and sensitivity, as calculated for 
satisfactory specimens, were achieved with the use of both FNAC and CB. False-positive 
and false-negative diagnoses were seen in 7/404 (1.7%) and 45/635 (7.1%) of biopsy-
proven specimens sampled by FNAC. FNAC is a valuable method, although moderately 
less sensitive than CB. FNAC is most accurate when experienced cytologists are 
available and when immediate assessment by professionals is performed for evaluation of 
material adequacy, so that additional aspirations can be done when needed. 
 
2) J Coll Physicians Surg Pak 2004 Nov;14(11):654-6    (ISSN: 1022-386X) 
Aziz M; Ahmad N;Zahid J;  Faizullah; Aziz M Department of General Surgery, Nishtar 
Medical College and Hospital, Multan. 
 
CONCLUSION: FNAC has good sensitivity (85.29%) and very high specificity (100%). 
It can replace the open biopsy in majority cases of clinically malignant disease. Although 
FNAC is slightly less sensitive (80%) in benign diseases, it is highly specific (100%), so 
it can help to reassure and relieve the anxiety of the patients. 
 
3) Fine-needle aspiration cytology vs. core biopsy in the diagnosis of breast lesions. 
Diagn Cytopathol 2003 Dec;29(6):344-8    (ISSN: 8755-1039) 
Berner A; Davidson B; Sigstad E; Risberg B Department of Pathology, Division of 
Cytology, The Norwegian Radium Hospital, University of Oslo, Montebello N-0310 
Oslo, Norway. 
 
High specificity and sensitivity, as calculated for satisfactory specimens, were achieved 
with the use of both FNAC and CB. False-positive and false-negative diagnoses were 
seen in 7/404 (1.7%) and 45/635 (7.1%) of biopsy-proven specimens sampled by FNAC. 
The corresponding values for CB were 0% and 5.7%, respectively. Inadequate sampling 
(15.1%) with use of FNAC was particularly seen in collagenous lesions and in submitted 
  
 
 
 
 
 
 
specimens sampled by physicians lacking experience with the FNAC procedure. FNAC 
is a valuable method, although moderately less sensitive than CB. CB is the preferred 
method for preoperative diagnosis when sampling FNAC provides scarce material and 
suspicion of a fibrotic and collagenous lesion such as lobular carcinoma and radial scar 
arises. FNAC is most accurate when experienced cytologists are available and when 
immediate assessment by professionals is performed for evaluation of material adequacy, 
so that additional aspirations can be done when needed 
 
4) A comparison of aspiration cytology and core needle biopsy in the evaluation of 
breast lesions. 
Cancer 2001 Apr 25;93(2):146-50    (ISSN: 0008-543X) 
Westenend PJ; Sever AR; Beekman –De Volder HJ; LiemSJ Laboratory for 
Pathology, Albert Schweitzer Hospital, Dordrecht, The Netherlands. 
 
RESULTS: Core needle biopsy and FNAC do equally well for sensitivity (88% vs. 
92%), positive predictive value for malignancy (99% vs. 100%), and inadequate rate (7% 
vs. 7%). However, statistical differences are found for the specificity (CNB, 90%; 
FNAC, 82%). In addition, differences are found in the positive predictive value of both 
suspicious (CNB, 100%; FNAC, 78%) and atypia (CNB, 80%; FNAC, 18%) and for the 
suspicious rate (CNB, 5%; FNAC, 13%) reflecting difficulties in interpreting some 
FNACs. Combining the findings of both FNAC and CNB results in an increase in 
absolute sensitivity, a decrease in the positive predictive value of atypia compared with 
FNAC and CNB per se, and a decrease in the inadequate rate for cancers. 
CONCLUSIONS: For the lesions selected in this study, FNAC and CNB are comparable 
for most parameters, but CNB has a higher specificity and lower suspicious rate. 
Combining results of FNAC and CNB leads to an increase in absolute sensitivity without 
affecting specificity and a decrease in the inadequate rate for cancers. 
 
5) Impact of inadequate fine-needle aspiration cytology on outcome of patients with 
palpable breast lesions. 
Aust N Z J Surg 2000 Sep;70(9):656-9    (ISSN: 0004-8682) 
Lee HC; OoiP J; Poh WT; Wong CY Department of General Surgery, Singapore General 
Hospital. 
 
BACKGROUND: The purpose of the present study was to assess the impact of 
inadequate fine-needle aspiration cytology (FNAC) breast specimens on the outcome 
of patients with a palpable breast lesion. RESULTS: One hundred and thirty-eight 
(16.6%) of 831 FNAC specimens were reported inadequate, and these form the study 
group. CONCLUSION: Breast cancer was present in 8.5% of the inadequate FNAC 
specimens. When clinical suspicion of malignancy is high, an excision biopsy is advised 
in patients with inadequate FNAC specimens. If properly managed with triple tests and 
good clinical judgement, the inadequate FNAC specimens do not delay treatment in 
patients with breast cancer. 
 
  
 
 
 
 
 
 
6) Randomized clinical trial of the effect of needle gauge and local anaesthetic on the 
pain of breast fine-needle aspiration cytology. 
Br J Surg 2000 Jun;87(6):777-9    (ISSN: 0007-1323) 
Daltrey IR; Kissin MW Department of Surgery, The Royal Surrey County Hospital, 
Guildford, UK. 
 
BACKGROUND: Breast fine-needle aspiration cytology (FNAC) is an invasive 
investigation which can be uncomfortable or distressing. This randomized study 
investigated the discomfort of breast FNAC and the effect of different techniques. 
METHODS: Some 116 FNAC samples were taken from 98 women with a palpable 
breast mass. Each patient was randomized to one of four study groups; aspiration was 
performed using a green-hub (21 G) or blue-hub (23 G) needle, either with or without 
local anaesthetic. Each patient scored the pain of the whole procedure using a visual 
analogue scale. RESULTS: A green-hub needle caused significantly more discomfort 
(mean(s.e.m.) pain score 5.1(0. 4) cm) than a blue-hub needle (2.9(0.4) cm), or either a 
blue- or green-hub needle with local anaesthetic (3.0(0.4) and 2.1(0.4) cm respectively) 
(F = 10.28, 3112 d.f., P < 0.01, analysis of variance). CONCLUSION: The discomfort of 
breast FNAC is dependent upon the gauge of the needle and the use of local anaesthetic. 
A blue-hub needle without local anaesthetic should be first choice for breast FNAC. 
 
7) Diagnostic accuracy of vacuum-assisted biopsy device for image-detected breast 
lesions. 
ANZ J Surg 2001 Aug;71(8):457-60    (ISSN: 1445-1433) Hung WK; Lam HS; Lau Y; 
Chan CM; Yip AW Department of Surgery, Kwong Wah Hospital, Hong Kong Special 
Administrative Region, China 
BACKGROUND: Non-palpable breast lesions present diagnostic difficulties. 
Ultrasound-guided fine-needle aspiration cytology (FNAC) is a common method used 
to obtain a diagnosis, but FNAC is frequently inconclusive or insufficiently accurate. 
Recently a vacuum-assisted biopsy device (Mammotome, Ethicon, Endo-surgery, USA) 
has been introduced. The diagnostic accuracy of this biopsy device was assessed for 
lesions that were visible on ultrasound. METHODS: Fifty ultrasound-guided 
mammotome biopsies were performed. All were small breast lesions primarily detected 
by ultrasound. All received FNAC as initial assessment. Mammotome biopsy was 
performed whenever the breast lesion was considered indeterminate or if it was 
considered benign and there were associated risk factors such as a family history of 
breast cancer. RESULTS: Of 50 mammotome biopsies 45 had benign histology. Three 
of 45 lesions were excised at the patients' request and were confirmed to be benign. The 
remaining 42 patients received an ultrasound follow up at 6 months. The lesion size 
remained static in 39 patients. In three patients the lesion size increased and they were 
excised and histology was benign. For the four malignancies diagnosed with 
mammotome biopsy, three patients received definitive treatment and one patient 
defaulted. There was one failed mammotome biopsy in the present series. 
CONCLUSIONS: Mammotome biopsy is an acceptable diagnostic method for small 
  
 
 
 
 
 
 
breast lesions seen on ultrasound. It reduces the need for open biopsy without 
compromising diagnostic accuracy. 
 
8) Fine needle aspiration cytology of the breast. Experience at an outpatient breast 
clinic. 
Acta Cytol 2000 May-Jun;44(3):361-7    (ISSN: 0001-5547) 
Kim A; Lee J; Choi JS; Won NH; Koo BH Department of Pathology, Korea University 
College of Medicine, Seoul, Korea. 
 
OBJECTIVE: To evaluate the accuracy of fine needle aspiration cytology (FNAC) of 
the breast at our institution and to perform quality assurance. STUDY DESIGN: Two 
hundred forty-six cases with pathologic confirmation were selected and reviewed. A 
pathologist performed most of the aspirations at an outpatient breast clinic. We 
correlated cytologic and histologic findings and evaluated the influence of the size, 
location, grade, and pathologic subtypes and fibrosis in breast lesions on diagnostic 
results. RESULTS: The likelihood ratios for malignant, suspicious, atypical, benign and 
unsatisfactory cytologic diagnoses were 98.71, 5.48, 1.09, 0.07 and 0.55, respectively. 
The absolute and complete sensitivities for malignant lesions were 64.5% and 90.3%, 
respectively. The specificity was 71.9%. False negative and positive rates were 4.3% and 
0.7%, respectively. The predictive value for a malignant cytologic diagnosis was 98.4%. 
The rate of unsatisfactory samples was 9.3%. The rate of concordance between cytologic 
and histologic diagnosis was lower for large and diffusely growing lesions (benign and 
malignant), for malignancies with abundant fibrosis and of unusual types and for 
carcinomas of low grade. All axillary and recurrent chest wall lesions were diagnosed 
cytologically. Cell block sections were useful in a small number of cases. 
CONCLUSION: Understanding the performance and limitations of FNAC can enhance 
its value as a diagnostic technique in the management of breast disease 
 
9) FNAC: its role, limitations and perspective in the preoperative diagnosis of breast 
cancer [In Process Citation]  
Eur J Gynaecol Oncol 2005;26(2):143-9 (ISSN: 0392-2936)  
Zagorianakou P; Fiaccavento S; Zagorianakou N; Makrydimas G; Agnantis NJ  
Department of Pathology, Medical School, University of Ioannina, Greece 
 
We conclude that FNAC plays an important and essential role in the management of 
patients with breast lesions and also offers a great potential for prediction of patient 
outcome, disease response to therapy and assessment of risk of developing breast cancer. 
The reliability and efficiency of the method depends on the quality of the samples and the 
experience of the medical staff that performs the aspiration 
 
10) Fine-needle aspiration cytology vs. core biopsy in the diagnosis of breast lesions.  
Diagn Cytopathol 2003 Dec;29(6):344-8 (ISSN: 8755-1039)  
Berner A; Davidson B; Sigstad E; Risberg B Department of Pathology, Division of 
Cytology, The Norwegian Radium Hospital, University of Oslo, Montebello N-0310 
Oslo, Norway 
  
 
 
 
 
 
 
 
 
High specificity and sensitivity, as calculated for satisfactory specimens, were achieved 
with the use of both FNAC and CB. False-positive and false-negative diagnoses were 
seen in 7/404 (1.7%) and 45/635 (7.1%) of biopsy-proven specimens sampled by FNAC. 
The corresponding values for CB were 0% and 5.7%, respectively. Inadequate sampling 
(15.1%) with use of FNAC was particularly seen in collagenous lesions and in submitted 
specimens sampled by physicians lacking experience with the FNAC procedure. FNAC 
is a valuable method, although moderately less sensitive than CB. CB is the preferred 
method for preoperative diagnosis when sampling FNAC provides scarce material and 
suspicion of a fibrotic and collagenous lesion such as lobular carcinoma and radial scar 
arises. FNAC is most accurate when experienced cytologists are available and when 
immediate assessment by professionals is performed for evaluation of material adequacy, 
so that additional aspirations can be done when needed. 
 
  
 
 
 
 
 
 
CONCLUSION 
The following conclusions were drawn from this study, 
The Percentage of Female Inpatients with Breast disorders (261) in TVMCH 
during this study period was 0.48 %. 
• The Percentage of female inpatients in TVMCH having Breast 
cancer (134) during this study period was 0.249 %. 
• Breast surgeries made up 1.49 % of all the major surgeries 
performed in TVMCH during this study period. 
1) The over all accuracy rate of FNAC was 87.92% and it reliably helped to plan 
the nature of Surgery to be undertaken. With Experience and use of Guidance 
techniques, the accuracy rate can be Improved to 94-96% at par with current 
international standards. 
2) The sensitivity of this study was 96.26 % for Breast malignancy, and         
95.32 % for benign breast disorders. 
3) FNAC can reliably diagnose Fibro Cystic disease and Surgery can be avoided 
for those patients. The 9 patients with FCD operated in this study had a Dominant, 
Symptomatic and Chronic lump, refractory to medical management. 
4) The predictive value of a Positive test for Malignancy was 96.26 % in this 
study. 
  
 
 
 
 
 
 
5) FNAC was reliable in diagnosing recurrent tumors and Metastatic nodes. 
6) Preoperative FNAC report and clinical diagnosis were both correlated 
before planning a Mastectomy and was Justified in all the patients who 
underwent Mastectomy. 
      7) There were no False positive cases this study. 
      8) FNAC was less accurate in diagnosising & confirming Medullary 
Carcinoma (50 %), Gynaecomastia (92.3 %) and Phyllodes (90.9 %). With 
experience and guidance techniques, there results can no doubt be improved upon. 
      9) FNAC can aid in the follow up of patients, with the least incidence of 
complication. In this study, there was a only a single case of Haematoma after 
FNAC in a case of Advanced IDC. 
   10)  There were totally 4 False Negative cases and most of then were due to 
sampling error, which can be brought down by experience. 
   11) Females obviously dominated the study with maximum incidence of breast 
tumors in the 20 to 60 years age group. 
  12)  In 1933,STEWART stated that “diagnosis by aspiration is as reliable as the 
 combined intelligence of the clinician and pathologist ,make it”. This wise 
 euphorism holds good for any study, and will influence the outcome of any 
 study. 
 
  
 
 
 
 
 
 
BIBLIOGRAPHY 
¾ BreastScreen Australia. National Accreditation Standards. Canberra ACT. 
 BreastScreen Australia Quality Improvement Program, 2001. 
¾ Australian Cancer Network Working Party. The pathology reporting of 
 breast cancer: a guide for pathologists, surgeons, radiologists and 
 oncologists. 2nd edn. Sydney:Australian Cancer Network, 2001. 
¾ National Breast Cancer Centre. Breast imaging: a guide for practice. 
 Camperdown,NSW: National Breast Cancer Centre, 2002. 
¾ Casey M, Rosenblatt R, Zimmerman J, Fineberg S. Mastectomy without 
 malignancy after carcinoma diagnosed by large-core stereotactic breast 
 biopsy. Mod Pathol 1997;10:1209–13. 
¾ Sneige N.Tulbah A.Accuracy of cytological diagnoses made from touch 
 imprints of image-guided needle biopsy specimens of non palpable  
  breast abnormalities. Diagn Cytopatho. 2000;23: 29–34. 
¾ Frost FA, Sterrett GF,Whitaker D et al. Core imprint cytology: a new 
 technique used in a breast assessment centre. Data presented at the 27th 
 Annual Scientific Meeting of the Australasian Division of the   
  International Academy of Pathology Limited. Sydney, June 2001. 
¾ Albert US, Duda V, Hadji P et al. Imprint cytology of core needle biopsy 
specimens of breast lesions.A rapid approach to detecting malignancies, with 
comparison of cytologic and histopathologic analyses of 173 cases. Acta Cytol 
2000;44:57–62. 
  
 
 
 
 
 
 
 
¾ NHMRC National Breast Cancer Centre. Psychosocial clinical practice 
 guidelines: providing information, support and counselling for women 
 with breast cancer. Canberra: Commonwealth of Australia, 2000. 
¾ Dahlstrom JE, Sutton S, Jain S. Histologic-radiologic correlation of 
 mammographically detected microcalcification in stereotactic core 
 biopsies. Am J Surg Pathol 1998;22:256–9. 
¾ Singh N,Wells CA.Assessment of accuracy in breast cytology. 
 Cytopathology 2001 Aug;12(4):211–8. 
¾ Hassell P, Klein-Parker H,Worth A, Poon P. Radial sclerosing lesions of the 
breast: mammographic and pathologic correlation. Can Assoc Radiol J 1999 
Dec; 50(6):370–75 
¾ Alvarado-Cabrero I,Tavassoli FA. Neoplastic and malignant lesions involving 
or arising in a radial scar: a clinicopathologic analysis of 17 cases. The Breast 
Journal 2000;6:96–102. 
¾ Lagios MD. Radial scars: a spiculate problem. The Breast Journal 2000;6:77. 
Denley H, Pinder SE,Tan PH et al. Metaplastic carcinoma of the breast arising 
within complex sclerosing lesion: a report of fivecases. Histopathology 
2000;36:203–9. 
¾ Cawson JN, Malara F, Kavanagh A,Hill P,Balasubramanium G, Henderson 
M. Fourteen-gauge needle core biopsy of mammographically evident radial 
scars: is excision necessary? 
Cancer. 2003 Jan 15;97(2):345–51. 
¾ Core biopsy versus FNAC for palpable breast cancers. Is image guidance 
necessary? Eur J Cancer 2003 Jan;39(1):52-6    (ISSN: 0959-8049) Agarwal 
T; Patel B; Rajan P; Cunningham DA; Darzi A; Hadjiminas DJ  
  
 
 
 
 
 
 
Breast Care Unit and Academic Surgical Unit,St Mary's Hospital, London, 
UK. 
¾ FNAC: its role, limitations and perspective in the preoperative diagnosis of 
breast cancer [In Process Citation]  
 Eur J Gynaecol Oncol 2005;26(2):143-9 (ISSN: 0392-2936)  
 Zagorianakou P; Fiaccavento S; Zagorianakou N; Makrydimas G;  Agnantis 
NJ Department of Pathology, Medical School, University of  Ioannina, Greece. 
¾ Fine-needle aspiration cytology vs. core biopsy in the diagnosis of breast 
lesions.  
 Diagn Cytopathol 2003 Dec;29(6):344-8 (ISSN: 8755-1039)  
 Berner A; Davidson B; Sigstad E; Risberg B  
 Department of Pathology, Division of Cytology, The Norwegian  Radium 
Hospital, University of Oslo, Montebello N-0310 Oslo 
¾ J Coll Physicians Surg Pak 2004 Nov;14(11):654-6    (ISSN: 1022-386X) 
Aziz M; Ahmad N;Zahid J;  Faizullah; Aziz M Department of General 
Surgery, Nishtar Medical College and Hospital, Multan. 
¾ Fine-needle aspiration cytology vs. core biopsy in the diagnosis of breast 
lesions. Diagn Cytopathol 2003 Dec;29(6):344-8    (ISSN: 8755-1039) 
Berner A; Davidson B; Sigstad E; Risberg B Department of Pathology, 
Division of Cytology, The Norwegian Radium Hospital, University of Oslo, 
Montebello N-0310 Oslo, Norway. 
¾ A comparison of aspiration cytology and core needle biopsy in the 
evaluation of breast lesions. Cancer 2001 Apr 25;93(2):146-50    (ISSN: 
0008-543X) Westenend PJ; Sever AR; Beekman –De Volder HJ; LiemSJ 
Laboratory for Pathology, Albert Schweitzer Hospital, Dordrecht, The 
Netherlands. 
¾ Randomized clinical trial of the effect of needle gauge and local anaesthetic 
  
 
 
 
 
 
 
on the pain of breast fine-needle aspiration cytology. Br J Surg 2000 
Jun;87(6):777-9    (ISSN: 0007-1323) Daltrey IR; Kissin MW Department of 
Surgery, The Royal Surrey County Hospital, Guildford, UK. 
¾ Diagnostic accuracy of vacuum-assisted biopsy device for image-detected 
breast lesions. ANZ J Surg 2001 Aug;71(8):457-60    (ISSN: 1445-1433) 
Hung WK; Lam HS; Lau Y; Chan CM; Yip AW Department of Surgery, 
Kwong Wah Hospital, Hong Kong Special Administrative Region, China 
¾ Fine needle aspiration cytology of the breast. Experience at an outpatient 
breast clinic. Acta Cytol 2000 May-Jun;44(3):361-7    (ISSN: 0001-5547) 
Kim A; Lee J; Choi JS; Won NH; Koo BH Department of Pathology, Korea 
University College of Medicine, Seoul, Korea. 
¾ Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. 
Immunohistochemical determination of oestrogen receptor: comparison of 
different methods of assessment of staining and correlation with clinical 
outcome of breast cancer patients. Br J Cancer. 1996;74:1445-1551. 
¾ Berg JW, Hutter RVP. Breast Cancer. Cancer. 1995;75:257-269.  
 Camplejohn RS, Ash CM, Gillett CE, et al. The prognostic significance  of 
DNA flow cytometry in breast cancer: results from 881 patients  treated  in a single 
centre. Br J Cancer. 1995;71:140-145. 
¾ Cannon-Albright LA, Skolnick MH. The genetics of familial breast cancer. 
Semin Oncol. 1996;23:1-5. 
¾ Elston CW, Ellis IO. Pathological prognostic faxtors in breast cancer. I. The 
value of histological grade in breast cancer: experience from a large study 
with long-term follow-up. Histopathology. 1991;19:403-410. 
¾ Fisher B, Costantino J, Redmond C, et al. Lumpectomy compared with 
lumpectomy and radiation therapy for the treatment of intraductal breast 
cancer. N Engl J Med. 1993;328:1581-1586. 
  
 
 
 
 
 
 
 
¾ Frierson HF Jr. Grade and flow cytometric analysis of ploidy for infiltrating 
ductal carcinomas. Hum Pathol. 1993;24:24-29. 
¾ Hedley DW. DNS Cytometry Consensus Conference. DNA flow cytometry 
and breast cancer. Breast Cancer Res Treat. 1993;28:51-53. 
¾ Henson DE, Ries LA, Carriaga MT. Conditional survival of 56,268 patients 
with breast cancer. Cancer. 1995;76:237-242. 
¾ Hitchcock A, Hunt CM, Locker A, et al. A one year audit of fine needle 
aspiration cytology for the pre-operative diagnosis of breast disease. 
Cytopathology. 1991;2:167-176. 
¾ King SE, Schottenfeld D. The "epidemic" of breast cancer in the U.S.--
determining the factors. Oncology. 1996;10:453-462, 464, 470-472. 
¾ Lee-Feldstein A, Anton-Culver H, Feldstein PJ. Treatment differences and 
other prognostic factors realted to breast cancer survival. JAMA. 
1994;271:1163-1168. 
¾ Leitch AM. Controversies in breast cancer screening. Cancer. 1995;76(10 
Suppl):2064-2069. 
¾ Peto J, Easton DF, Matthews FE, Ford D, Swerdlow AJ. Cancer mortality in 
relatives of women with breast cancer. Int J Cancer. 1996;65:275-283. 
¾ Pichon MF, Broet P, Magdelenat H, et al. Prognostic value of steroid 
receptors after long-term follow-up of 2257 operable breast cancers. Br J 
Cancer. 1996;73:1545-1551. 
¾ Robbins P, Pinder S, deKlerk N, et al. Histological grading of breast 
carcinomas: a study of interobserver variation. Hum Pathol. 1995;26:873-879. 
¾ Steinberg JL, Trudeau ME, Ryder DE, et al. Combined fine-needle aspiration, 
physical examination and mammography in the diagnosis of palpable breast 
masses: teir relation to outcome for women with primary breast cancer. Can J 
Surg. 1996;39:302-311. 
  
 
 
 
 
 
 
PROFORMA 
 
1. CASE NO: 
2. NAME  :   AGE :  SEX : 
            ADDRESS            :   OCCUPATION & INCOME : 
 
 
 
DATE OF ADMISSION :   DATE OF SURGERY : 
DATE OF DISCHARGE : 
 
3. PRESENTING COMPLAINTS : 
 (a) lump : 1) Site     Number : 
   2) Duration      
   3) Nature / Consistency 
   4) Rate of growth 
 
 (b) pain :  (1) Whether associated with pain  YES / NO 
   (2) If yes, nature of pain  : 
   (3) Any radiation  : 
   (4) Precipitating factors  : 
   (5) Relieving factors   : 
 (c) nipple : (1a) Retraction :    YES / NO 
   (1b) If yes, time of onset : 
   (2) Nipple discharge : bloody/serous/greenish/milky/others/ nil 
 (d) Bone pain if any   : 
 (e) Malaise / fatigability  : 
 (f) Others    : 
  
 
 
 
 
 
 
 
4. PAST HISTORY : 
(a) h/o of previous lumps if any   : 
(b) h/o cyclical mastagia if any  : 
(c) h/o any treatment for breast lumps : 
(d) h/o previous surgeries for lumps if any : 
(e) other relevent h/o    : 
5. PERSONAL HISTORY : 
(a) habits : tobacco / alchohol / others / nil. 
(b) diet  : mixed / vegetarian. 
(c) appetite : good / loss of appetite. 
(d) bowel movements : regular / constipation / diarrhoea / malena / haematochezia 
(e) bladder movements :  
(f) personal hygiene   : good / moderate / poor. 
6. MENSTRUAL H/O :  premenopausal / postmenopausal : 
(a) age at menarche : 
(b) period cycle : regular / irregular 
(c) age at menopause if postmenopausal : 
(d) h/o of menstrual regulation if any : 
(e) h/o of oral contraceptive pill intake :   Yes / No 
(f) if yes, time and duration of intake : 
(g) complication if any  : 
(h) h/o of D & C if any  : 
7. FAMILY H/O 
(a) whether married   : 
(b) duration of married life  : 
(c) no of children   : Male / Female / Nil 
(d) h/o previous abortions / still births if any : 
(e) h/o of contraception  : 
(f) h/o of similar lumps in family / relative : 
  
 
 
 
 
 
 
(g) h/o of surgery for lump breast in family / relatives : 
(h) if yes, degree of relation   : 
8. GENERAL PHYSICAL EXAMINATION  
(a) Vital signs :  Pulse:  Blood Pressure :        Heart Rate : 
   Temperature :  Respiratory Rate : 
(b) Built and nutrition : 
(c) State of hydration  : 
(d) Evidence of anaemia / jaundice / clubbing / cyanosis / pedal edema /     
      lymphedema generalized lymphadenopathy : 
9. EXAMINATION OF THE BREAST : 
(a) Inspection : (Examination done with arms by the side of the patient, arms 
raised straight above, arms on the hips and on bending forward) 
1) Nipple  :  
Position  : 
Size and Shape : Prominent / Flattened / Retracted 
Surface : 
Discharge if any : 
                 2) Areola  : 
      3) Lump, if visible  : 
  Position  : 
  Size and Shape : 
  Surface  : 
  Number  : 
                4) Skin over the breast : 
  Colour   : Redness / Shininess / Others. 
  Engorged veins : 
  Surface  :Dimpling / Retraction / Puckering / Others. 
  Ulcers   : 
  Advanced signs : Peaud’ orange/Cancer en cuirasse/Fungation  
       /Others 
  
 
 
 
 
 
 
    5) The opposite breast : 
    6) Any arm lymphedema : 
(b) Palpation : 
 1) Local temperature and tenderness : 
 2) Situation of lump   : 
 3) Number    : 
 4) Size and Shape   : 
 5) Surface    : Smooth / Irregular / Other 
 6) Margin    : 
 7) Consistency   : 
 8) Fixity to skin over the breast :  Tethering / Puckering / Retraction / Nil. 
 9) Fixity to the breast tissue  : 
 10) Fixity to the underlying fascia & Muscles : 
 11) Fixity to the chest wall  : 
 12) Transillumination   : 
 13) Ulcer    : 
 14) Examination of lymphnode regions: Number/Size/ Consistency /Mobility /  
           Others 
  Anterior (Pectoral)  : 
  Posterior (Subscapular) : 
  Medial    : 
  Lateral (Brachial)  : 
  Central   : 
  Apical    : 
  Other regions   : 
  Opposite axilla  : 
 15) The opposite breast  : 
 16) Percussion    : 
 17) Ausculation   : Bruit / Others. 
 
  
 
 
 
 
 
 
10) EXAMINATION OF OTHER SYSTEMS 
 (a) Abdomen    : 
  Shape / Surface  : 
  Movement with respiration : 
  Umbilicus   : 
  Organomegaly if any  : 
  Abdominal mass if any : 
  Ascitis if any   : 
  Per vaginal examination : 
  Per rectal examination : 
 (b) Cardiovascular system  : 
 (c) Respiratory system  : 
 (d) Central nervous system  : 
 
11) CLINICAL DIAGNOSIS AND STAGING : 
 
 
12) INVESTIGATION : 
 (a) Routine labs :1) Blood Hb% TC  DC  BT CT 
          Blood grouping and typing : 
          Blood : Urea Mgs%. Sugar Mgs%.s.creatinine Mgs% 
       2) Urine :albumin  Sugar  Deposites 
       3) ECG in all leads : 
 (b) Special :  
      i) Non invasive : 
  1) X-ray chest pa view  : 
  2) Mammography finding  : 
  3) Ultra sound breast   : 
  4) CT / Others if any   : 
  5) Nipple discharge cytology and analysis if any : 
  
 
 
 
 
 
 
       (ii) Invasive investigations  : 
  1) Fine needle aspiration cytology : 
  2) CT / USG guided biopsies if any : 
 
13) PRE OPERATIVE DIAGNOSIS AND TREATMENT PLAN : 
 
14) PRE OPERATIVE PREPARATION : 
15) OPERATIVE DETAILS : 
 (a) Surgery done   : 
 (b)Procedure    : bcs / radical / palliative / toilet / others 
 (c) Axillary lymphnode dissection : 
 (d) Closure    : 
 (e) Preoperative complications if any : 
16) POSTOPERATIVE PERIOD : 
 (a) Complications if any  : 
 (b) Skin graft for raw area in chest wall if any : 
 (c) If yes    : Primary / delayed 
17) POST OPERATIVE DIAGNOSIS : 
 (a) FNAC REPORT  : 
 
 
 (b) HISTOPATHOLOGY REPORT : 
 
 (c) CORRELATION   : 
 
 (d) REMARKS   : 
18) POST OPERATIVE TREATMENT : 
 (a) Chemotherapy   : 
 (b) Radiotherapy   : 
 (c) Hormone therapy   : 
  
 
 
 
 
 
 
19) POST OPERATIVE FOLLOW UP AND OUTCOME : 
(a) Chemothrapy schedule  : 
(b) Radiotherapy   : 
 
20) REMARKS    : 
  
 
 
 
 
 
 
MASTER CHART 
 
S.No. Name Age/ 
Sex 
IP No. FNAC Report Surgery 
Done 
HPE 
No. 
HPE Report 
1. Mookammal 45/F 182886 DC MRM 298/03 IDC 
2. Velammal 47/F 184546 DC MRM 347/03 IDC 
3. Muthu 19/F 183011 FA Excision 353/03 FA 
4. Oorkali 31/F 185636 FA Excision 369/03 FA 
5. Muthukani 29/F 185636 FA Excision 370/03 FA 
6. Karpagam 40/F 185127 FA Excision 374/03 FA 
7. Aundiammal 50/F 185978 DC MRM 421/03 IDC 
8. Sivasodevar 37/F 187035 FA Excision 423/03 FA 
9. Araichimani 58/F 187033 DC MRM 440/03 IDC 
10. Savariammal 88/F 186723 DC MRM 441/03 IDC 
11. Marimuthu 17/M 187816 GM Websters 445/03 GM 
12. Mariammal 29/F 186930 FA Excision 463/03 FA 
13. Seriammal 29/F 186942 DC MRM 465/03 IDC 
14. Grazy 38/F 188072 DC MRM 484/03 IDC 
15. Arputham 34/F 189722 DC MRM 506/03 IDC 
16. Anandhi 21/F 190228 DC MRM 506/03 IDC 
17. Thangam 50/F 191130 DC MRM 523/03 IDC 
18. Ramani 38/F 187924 DC MRM 531/03 IDC 
19. Nasiammal 40/F 190227 FCD Excision 553/03 FCD 
20. Vasantha 40/F 190229 DC MRM 557/03 IDC 
21. Thoulath 19/F 192521 FA Excision 563/03 FA 
22. Muthulakshmi 31/F 191974 Acellular 
smear 
Excision 566/03 FA 
23. Saraswathi 21/F 191970 FA Excision 569/03 FA 
24. Annalakshmi 19/F 193423 FA Excision 597/03 FA 
25. Ariyanatchi 20/F 183658 FA Excision 614/03 FA 
26. Murugakani 22/F 193933 FA Excision 625/03 FA 
27. Petchiammal 20/F 194577 FA Excision 643/03 FA 
28. Rajalakshmi 25/F 194577 FA Excision 652/03 FA 
29. Mariasuseela 19/F 192733 FA Excision 652/03 FA 
30. Essakiammal 19/F 194425 FA Excision 654/03 FA 
31. Janaki 55/F 194691 DC MRM 667/03 IDC 
32. Vasantha 35/F 195380 DC MRM 672/03 IDC 
33. Angaleshwari 55/F 194930 DC MRM 712/03 IDC 
34. Arumugan 37/F 197924 Suspicion of 
malignancy 
MRM 729/03 IDC 
35. Pitchammal 20/F 194597 FA Excision 759/03 FA 
36. Arumugakani 32/F 193933 FA Excision 761/03 FA 
  
 
 
 
 
 
 
37. Lakshmi 58/F 198061 DC MRM 775/03 IDC 
38. Mariammal 45/F 198198 DC MRM 781/03 IDC 
39. Saraswathi 52/F 195181 PHYLLODES SM 787/03 PHYLLODES 
40. Poonal 40/F 198384 FA Excision 796/03 FA 
41. Kuruvammal 26/F 198381 FA Excision 797/03 FA 
42. Mariammal 32/F 198439 DC MRM 803/03 IDC 
43. Anandaselvan 17/M 198856 GM Websters 809/02 GM 
44. Rosemari 28/F 198893 DC MRM 812/03 IDC 
45. Antony 28/M 194221 GM Websters 815/03 GM 
46. Sankar 24/M 199616 GM Websters 821/03 GM 
47. Vellathai 60/F 195560 DC MRM 822/03 IDC 
48. Arumugam  37/F 199150 DC MRM 812/03 IDC 
49. Vijayalakshmi 38/F 200548 DC MRM 848/03 IDC 
50. Fathima 50/F 199800 DC MRM 851/03 IDC 
51. Mariammal 45/F 199085 DC MRM 857/03 IDC 
52. Muthulakshmi 70/F 200120 Suspicious of 
malignancy 
SM 868/03 MALIGNANT 
PHYLLODES 
53. Vasanthi 27/F 215833 FA Excision  FA 
54. Vaikundar 21/M 200827 GM Websters 886/03 GM 
55. Annakili 61/F 221913 DC MRM 891/03 IDC 
56. Pappathy 40/F 201125 DC MRM 896/03 IDC 
57. Saraswathy 45/F 201404 Suspicious of 
malignancy 
MRM 905/03 IDC 
58. Gandhi 55/M 201292 GM Websters 920/03 GM 
59. Nadatchi thangam 50/F 201568 DC MRM 921/04 IDC 
60. Lakshmi 50/F 202513 DC MRM 936/03 IDC 
61. Chellammal 57/F 202499 DC MRM 959/03 IDC 
62. Aathikani 42/F 202637 FA SM 960/03 PHYLLODES 
63. Selvan 32/M 202483 GM Websters 962/03 GM 
64. Parvathi 51/F 202628 DC MRM 964/03 IDC 
65. Vanaja 50/F 204554 DC MRM 1014/03 IDC 
66. Ruby 47/F 203853 DC MRM 1016/03 IDC 
67. Selvi 35/F 203401 DC MRM 1017/03 IDC 
68. Sangaershwari 34/F 204152 DC MRM 1019/03 IDC 
69. Pushpa 19/F 204271 FA Excision 1020/03 FA 
70. Rajan 25/M 204100 acellular 
smear 
Websters 1021/03 GM 
71. Janaki 32/F 204907 FA Excision 1023/03 FA 
72. Balassubramanian 29/M 204800 GM Websters 1032/03 GM 
73. Paulthangam 43/F 206099 DC MRM 1040/03 IDC 
74. Vellaiammal 25/F 204549 FA Excision 1050/03 FA 
75. Nirmala 25/F 206435 FA Excision 1051/03 FA 
76. Alagurathi 42/F 206170 DC MRM 1101/03 IDC 
  
 
 
 
 
 
 
77. Mothai 48/F 210198 DC MRM 1166/03 IDC 
78. Jeyakani 37/F 212785 FA Excision 70/04 FA 
79. Jesuchristian 58/F 211549 FA Excision 21/04 FA 
80. Visalatchi 72/F 209931 DC MRM 26/04 IDC 
81. Malliga 54/F 212154 DC MRM 29/04 IDC 
82. Gandhi 26/F 213033 FA Excision 33/04 FA 
83. Ambika 20/F 213279 FA Excision 38/04 FA 
84. Sitammal 33/F 209568 FA Excision 53/04 FA 
85. Mahalakshmi 30/F 208752 FA Excision 55/04 FA 
86. Perumalammal 50/F 212025 DC MRM 57/04 IDC 
87. Annalakshmi 45/F 209784 DC MRM 59/04 IDC 
88. Sivakami 30/F 215548 DC MRM 102/04 IDC 
89. Pitchammal 55/F 215430 DC MRM 116/04 IDC 
90. Ramachandran 42/M 214495 FA Excision 125/04 FA 
91. Saraswathu 47/F 215855 FCD Excision 134/04 FCD 
92. Ganapthivalli 21/F 217217 FCD Excision 148/04 FCD 
93. Karpagam 42/F 217251 FA Excision 165/04 FA 
94. Gothiammal 60/F 216229 DC MRM 169/04 IDC 
95. Mariammal 57/F 217744 DC MRM 177/04 IDC 
96. Vilashini 45/F 217940 DC MRM 186/04 IDC 
97. Sudaiammal 50/F 215583 DC MRM 207/04 IDC 
98. Subbulakshmi 41/F 217648 FA SM 210/04 PHYLLODES 
99. Gandhiammal 45/F 217576 DC MRM 219/04 IDC 
100. Periyaratchi 60/F 215561 DC MRM 238/04 IDC 
101. Petchithai 45/F 218593 DC MRM 242/04 IDC 
102. Rajendran 35/M 219783 GM Websters 246/04 GM 
103. Latha 45/F 215828 DC MRM 248/04 IDC 
104. Annammal 55/F 219803 DC MRM 250/04 IDC 
105. Karpagam 25/F 220546 FA Excision 271/04 FA 
106. Krishnammal 51/F 220562 FA Excision 272/04 FA 
107. Chandra 22/F 220553 FA Excision 273/04 FA 
108. Iyyammal 42/F 218933 PHYLLODES SM 341/04 PHYLLODES 
109. Punitha 23/F 223205 FA Excision 399/04 FA 
110. Kamatchi 70/F 222804 FCD Excision 413/04 FCD 
111. Chandrakani 27/F 2241032 FA Excision  FA 
112. Duraitchi 40/F 223999 Suspicious of 
malignancy 
MRM 429/04 IDC 
113. Chellathai 55/F 221375 FCD Excision 433/04 FCD 
114. Ramalakshmi 19/F 223998 FA Excision 444/04 FA 
115. Motharani 19/F 224916 FA Excision 455/04 FA 
116. Karupayeeammal 70/F 225504 DC MRM 466/04 IDC 
117. Subbulakshmi 37/F 223971 DC MRM 469/04 IDC 
118. Chitra 37/F 225627 FA SM 578/04 PHYLLODES 
  
 
 
 
 
 
 
119. Gnanasundari 24/F 226290 FA Excision 519/04 FA 
120. Kumar 17/M 226438 GM Websters 521/04 GM 
121. Peer Mohammed 13/M 227240 GM Websters 554/04 GM 
122. Sethuraman 18/M 227236 GM Websters 556/04 GM 
123. Surah 30/F 227942 IDC MRM 570/04 IDC 
124. Murugesh 15/M 228173 GM Websters 573/04 GM 
125. Subramanian 20/M 227011 GM Websters 574/04 GM 
126. Petchiammal 27/F 227464 FA Excision 555/04 FA 
127. Sahayarani 40/F 227915 DC MRM 581/04 IDC 
128. Arumugammal 45/F 226281 DC MRM 589/04 IDC 
129. Balammal 22/F 228045 FA Excision 590/04 FA 
130. Nagoormeeral 23/F 228093 FA Excision 591/04 FA 
131. Asulammal 26/F 228285 FA Excision 597/04 FA 
132. Leelavathi 19/F 228092 FA Excision 800/04 FA 
133. Lakshmi 28/F 251995 FA Excision 1503/04 FA 
134. Masood Beevi 55/F 251791 DC MRM 1513/04 IDC 
135. Kavitha 26/F 262905 FA Excision 1514/04 FA 
136. Ramalakshmi 28/F 252270 FA Excision 1516/04 FA 
137. Subbulakshmi 65/F 252272 DC MRM 1521/04 IDC 
138. Sudalaimuthu 15/M 252402 GM Websters 1536/04 GM 
139. Petchiammal 22/F 253646 FA Excision 1552/04 FA 
140. Geetha 40/F 252859 Suspicious of 
malignancy 
MRM 1554/04 MEDULLARY 
CARCINOMA 
141. Subbulakshmi 65/F 253017 DC MRM 1556/04 IDC 
142. Antony 48/M 254177 GM Websters 1560104 GM 
143. Ramjan Begam 36/F 255007 DC MRM  IDC 
144. Kandammal 45/F 259916 DC MRM 1606/04 IDC 
145. Vasantha 33/F 259183 FA Excision 1615/04 FA 
146. Sarojini Devi 49/F 254726 DC MRM 1638/04 IDC 
147. Muthulakshmi 32/F 256391 PHYLLODES SM 2/05 PHYLLODES 
148. Udavammal 70/F 256313 DC MRM 32/05 IDC 
149. Kasim Beevi 24/F 256639 FA Excision 45/05 FA 
150. Madathy 42/F 256003 FA Excision 46/05 FA 
151. Indira 21/F 256007 FA Excision 51/05 FA 
152. Essakiammal 60/F 257354 DC MRM 96/05 IDC 
153. Mary 53/F 254512 DC MRM 97/05 IDC 
154. Serdu 45/F 256368 Suspicious of 
malignancy 
MRM 119/05 IDC 
155. Santakumari 18/F 813 FA Excision 133/05 FA 
156. Ulagammal 50/F 499 FA Excision 149/05 FA 
157. Geetha 45/F 790 DC MRM 156/05 IDC 
158. Nargees Banu 31/F 2433 PHYLLODES SM 214/05 PHYLLODES 
159. Arifa 39/F 1680 DC MRM 223/05 IDC 
  
 
 
 
 
 
 
160. Maheshwari 17/F 3374 FA Excision 242/05 FA 
161. Sudha 19/F 3377 FA Excision 243/05 FA 
162. Selva Pannu 42/F 2802 DC MRM 249/05 IDC 
163. Kala 39/F 2806 DC MRM 250/05 IDC 
164. Kalaiselvi 40/F 255793 PHYLLODES SM 251/05 PHYLLODES 
165. Poomari 31/F 3822 FA Excision 288/05 FA 
166. Subbulakshmi 50/F 2918 DC MRM 289/05 IDC 
167. Subbiah Thevar 54/M 3084 DC MRM 290/05 IDC 
168. Fathima 70/F 1487 DC MRM 355/05 IDC 
169. Pappa 58/F 1479 DC MRM 356/05 IDC 
170. Parvathy 58/F 3718 DC MRM 381/05 IDC 
171. Lakshmi 45/F 6057 DC MRM 403/05 IDC 
172. Muthulakshmi 33/F  FA Excision 405/05 FA 
173. Parvathy 30/F 4872 DC MRM 409/05 IDC 
174. Poongani 70/F 5748 DC MRM 417/05 IDC 
175. Lakshmi 70/F 5795 DC MRM 421/05 IDC 
176. Mariammal 21/F 7121 FA Excision 432/05 FA 
177. Suffammal 69/F 7281 DC MRM 463/05 IDC 
178. Subbulakshmi 71/F 8342 DC MRM 477/05 IDC 
179. Paul Durai 28/M 8344 GM Websters 489/05 GM 
180. Selvalakshmi 20/F 8551 FA Excision 497/05 FA 
181. Anand 31/M 9609 GM Websters 498/05 GM 
182. Arumugalakshmi 15/F 9839 FA Excision 501/05 FA 
183. Selvalakshmi 27/F 9874 FA Excision 512/05 FA 
184. Selvi 33/F 2959 FCD Excision 518/05 FCD 
185. Lakshmi 50/F 10045 DC MRM 524/05 IDC 
186. Fathima 30/F 11080 FA Excision 536/05 FA 
187. Saraswathy 35/F 10661 DC MRM 546/05 IDC 
188. Vijayasundai 16/F 11758 FA Excision 576/05 FA 
189. Subbulakshmi 70/F 5342 DC MRM 580/05 IDC 
190. Singari 40/F 11079 DC MRM 610/05 IDC 
191. Suseela 39/F 13575 Medullary 
Carcinoma 
MRM 630/05 MEDULLARY
CARCINOMA 
192. Subbiah 44/M 11632 GM Websters 640/05 GM 
193. Kaliyammal 41/F 12878 FA Excision 614/05 FA 
194. Rajammal 55/F 11339 DC MRM 650/05 IDC 
195. Indira 35/F 12331 DC MRM 651/05 IDC 
196. Vellammal 36/F 13403 FA Excision 665/05 FA 
197. Krishnammal 55/F 13759 DC MRM 676/05 IDC 
198. Sivakami 55/F 13043 DC MRM 685/05 IDC 
199. Arulthangam 16/F 14063 FA Excision 690/05 FA 
200. Sarojini 58/F 14783 DC MRM 728/05 IDC 
201. Sheela 20/F 15442 FA Excision 741/05 FA 
  
 
 
 
 
 
 
202. Muthulakshmi 16/F 16436 FA Excision 763/05 FA 
203. LakshmiNarayanan 18/M 16694 Acellular 
smear 
Websters 769/05 GM 
204. Ramesh 32/M 15074 GM Websters 773/05 GM 
205. Bhagya Thai 65/F 15186 DC MRM 811/05 IDC 
206. Annathai 58/F 16899 DC MRM 812/05 IDC 
207. Subbammal 60/F 14792 DC MRM 815/05 IDC 
208. Alphonse Maryt 46/F 15770 DC MRM 824/05 IDC 
209. Poomani 53/F 20097 PHYLLODES SM 851/05 PHYLLODES 
210. Sundari 23/F 21615 FA Excision 857/05 FA 
211. Vellammal 68/F 20177 DC MRM 868/05 IDC 
212. Muppidathi 59/F 22652 FA Excision   905/05 FA 
213. Revathy 25/F 23445 FA Excision 927/05 FA 
214. Duraimuthu 60/M 23435 GM Websters 934/05 GM 
215. Rajammal 65/F 22651 DC MRM 938/05 IDC 
216. Muthumari 14/F 25655 FA Excision 963/05 FA 
217. Rani 26/F 27141 FA Excision 1032/05 FA 
218. Subbulakshmi 17/F 28128 FA Excision 1053/05 FA 
219. Sundaram 52/F 25708 DC MRM 1054/4 IDC 
220. Parvathyammal 68/F 25345 DC MRM 1070/05 IDC 
221. Devakani 47/F 16784 FA Excision 1084/05 FA 
222. Thavasiammal 38/F 28245 PHYLLODES SM 1106/05 PHYLLODES 
223. Saraswathy 24/F 28184 FA Excision 1127/05 FA 
224. Prema 42/F 28502 DC MRM 1139/05 IDC 
225. Muthammal 30/F 29395 FA Excision 1154/05 FA 
226. Vanitha 22/F 30812 FA Excision 1188/05 FA 
227. Prema 42/F 28502 DC MRM 1140/05 IDC 
228. Mohammad 30/F 29395 FA Excision 1154/05 FA 
229. Arpudam 49/F 31345 FCD Excision 1208/05 FCD 
230. Chandra 38/F 32156 FA Excision 1214/05 FA 
231. Krishraveri 26/F 31660 FA Excision 1233/05 FA 
232. Shyamala 49/F 29812 FCD Excision 1247/05 FCD 
233. Karuppayi 64/F 22674 DC MRM 1272/05 IDC 
234. Mariappan 19/M 32144 GM Websters 1273/05 GM 
235. Balakrishnan 13/M 33271 GM Websters 1286/05 GM 
236. Sundari 56/F 32541 DC MRM 1319/05 IDC 
237. Vennila 50/F 32924 DC MRM 1326/05 IDC 
238. Navikithai 34/F 32598 DC MRM 1329/05 IDC 
239. Selvakani 38/F 24282 DC MRM 1349/05 IDC 
240. Anthony Ammal 51/F 34995 DC MRM 1352/05 IDC 
241. Gomadevi 30/F 35045 FA Excision 1353/05 FA 
242. Sudali 27/F 35171 FA Excision 1359/05 FA 
243. Nagammal 53/F 34580 DC MRM 1365/05 IDC 
  
 
 
 
 
 
 
244. Parameswari 19/F 37779 FA Excision 1372/05 FA 
245. Karapagavalli 27/F 36964 FA Excision 1424/05 FA 
246. Mariammal 19/F 36343 FA Excision 1441/05 FA 
247. Amalapushpam 70/F 38541 DC MRM 1459/05 IDC 
248. Selvi 25/F 36908 FA Excision 1461/05 FA 
249. Muthulakshmi 40/F 39017 FA Excision 1468/05 FA 
250. Lakshmi 42/F 38205 DC MRM 1474/05 IDC 
251. Guru 18/F 39272 FA Excision 1555/05 FA 
252. Gomathiammal 42/F 41182 FA Excision 1558/05 FA 
253. Shanthi 42/F 42124 DC MRM 1559/05 IDC 
254. Anandhi 55/F 44023 DC MRM 1606/05 IDC 
255. Sarojini 64/F 43235 DC MRM 1610/05 IDC 
256. Bhuvaneshwari 19/F 43234 FA Excision 1627/05 FA 
257. Vasanthi 35/F 41021 FA Excision 1643/05 FA 
258. Subbulakshmi 35/F 41027 FA Excision 1655/05 FA 
259. Kalivardhan 24/M 41947 GM Excision 1670/05 GM 
260. Sornakili 37/F 44610 DC MRM 1689/05 IDC 
261. Manju 27/F 41663 DC MRM 1692/05 IDC 
262. Antonyammal 52/F 46351 DC MRM 1702/05 IDC 
263. Muthulakshmi 35/F 45647 FA Excision 1713/05 FA 
264. Aruna 35/F 42863 FA Excision 1714/05 FA 
265. Arulmari 65/F 42868 DC MRM 1730/05 IDC 
266. Guruvammal 34/F 45878 DC MRM 1745/05 IDC 
267. Sornalakshmi 51/F 46083 DC MRM 1796/05 IDC 
268. Ramalakshmi 50/F 47395 DC MRM 1766/05 IDC 
269. Sornam 37/F 44610 DC MRM 1768/05 IDC 
270. Sokammal 55/F 43758 DC MRM 1769/05 IDC 
271. Rani 44/F 43090 DC MRM 1781/05 IDC 
272. Kalpana 16/F 47609 DC MRM 1784/05 IDC 
273. Vasanthi 38/F 48320 DC MRM 49/06 IDC 
274. Mookammal 55/F 47891 BP SM 56/06 BP 
275. Muthumari 23/F 47933 FA Excision 58/06 FA 
276. Kalavathy 18/F 48544 FA Excision 60/06 FA 
277. Meenakshi 50/F 48777 DC MRM 80/06 IDC 
278. Devamari 22/F 2064 FA Excision 100/06 FA 
279. Mookammal 47/F 2027 DC MRM 107/06 IDC 
280. Poonkili 19/F 2562 FA Excision 116/06 FA 
281. Daulath 30/F 1553 FA Excision 120/06 FA 
282. Saroja 53/F 1033 DC MRM 151/06 IDC 
283. Rringo 24/F 1044 FA Excision 153/06 FA 
284. Gomathy 33/F 4689 FDC Excision 200/06 FDC 
285. Ambika 35/F 2790 FA Excision 201/06 FA 
286. Lakshmi 42/F 4335 DC MRM 213/06 IDC 
  
 
 
 
 
 
 
287. Melammal 22/F 5908 FA Excision 236/06 FA 
288. Selvi 25/F 4992 DC MRM 289/06 IDC 
289. Pappa 50/F 5028 DC MRM 303/06 IDC 
 
IDC    - INFILTRATING DUCTAL CARCINOMA             FA    -      FIBRO ADENOMA. 
FCD   - FIBRO CYSTIC DISEASE                     GM   -      GYNAECOMASTIA. 
BP     - BENIGN PHYLLODES TUMOR                    MP    -      MALIGNANT PHYLLODES 
MC   - MEDULLARY CARCINOMA                                DC     -       DUCTAL CARCINOMA
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